Structural and Functional Characterization of Neurotoxic Oligomers of Pro-aggregant Tau Repeat Domain : A model for Tauopathy disease by Kaniyappan, Senthilvelrajan
 Structural and Functional Characterization  
of Neurotoxic Oligomers of  
Pro-aggregant Tau Repeat Domain :  



























 Angefertigt mit Genehmigung der Mathematisch-Naturwissenschaftlichen 
























1. Gutachter : Prof. Dr. Eckhard Mandelkow 
2. Gutachter : Prof. Dr. Micheal Hoch 
 
 









Abbreviations ........................................................................................................... iv 
Summary .................................................................................................................. vi 
List of tables .......................................................................................................... viii 
List of figures ......................................................................................................... viii 
1 Introduction ...................................................................................................... 1 
1.1 Neurodegenerative diseases ......................................................................... 1 
1.2 Tauopathies ................................................................................................... 1 
1.3 Tau and Alzheimer disease ........................................................................... 2 
1.3.1 Tau protein structure ............................................................................... 2 
1.3.2 Functions of Tau protein ......................................................................... 5 
1.3.3 Changes of Tau in Alzheimer disease .................................................... 7 
1.3.4 Tau aggregation ...................................................................................... 8 
1.3.5 Toxicity of Tau aggregates .................................................................... 11 
1.3.6 Small soluble Tau oligomers ................................................................. 13 
1.4 Inhibition of Tau aggregation ....................................................................... 15 
2 Aims of the study: .......................................................................................... 17 
3 Materials and Methods................................................................................... 18 
3.1 Materials (Instruments and equipment) ....................................................... 18 
3.1.1 Centrifuges ............................................................................................ 18 
3.1.2 HPLC .................................................................................................... 18 
3.1.3 Columns ................................................................................................ 18 
3.1.4 Spectrophotometers .............................................................................. 18 
3.1.5 Microscopes .......................................................................................... 19 
3.1.6 Cell culture equipment .......................................................................... 19 
3.1.7 Others ................................................................................................... 19 
3.1.8 Chemicals ............................................................................................. 20 
3.2 Methods ....................................................................................................... 21 
3.2.1 Protein preparation and purification ...................................................... 21 
3.2.2 Determination of protein concentration (BCA assay) ............................ 22 
3.2.3 Aggregation of TauRDΔ .......................................................................... 22 
3.2.4 Separation of oligomers of TauRDΔ ........................................................ 24 
3.2.5 Biophysical methods ............................................................................. 26 
3.2.6 Imaging methods: ................................................................................. 28 




3.2.8 Tissue culture ........................................................................................ 37 
3.2.9 Animal models ...................................................................................... 38 
3.2.10 Statistics................................................................................................ 39 
4 Results ............................................................................................................ 40 
4.1 Oligomers interact via cys-cys bonding in ΔK280 transgenic mice .............. 40 
4.2 Separation of Tau oligomers by iodixanol gradient centrifugation ............... 41 
4.3 Preparation of TauRDΔ protein in vitro .......................................................... 44 
4.4 Aggregation kinetics of TauRDΔ .................................................................... 45 
4.4.1 Aggregation monitored by light scattering and fluorescence assays ..... 45 
4.4.2 EM and AFM reveal twisted fibrils and oligomeric structures ................ 48 
4.4.3 Purification of oligomers by size exclusion chromatography ................. 49 
4.5 Stabilization of TauRDΔ oligomers ................................................................ 51 
4.5.1 Reduction of Tau aggregation by EGCG .............................................. 51 
4.5.2 EM reveals that EGCG reduces fibril length and increases oligomers .. 52 
4.5.3 EGCG increases SDS resistant soluble TauRDΔ oligomers ................... 53 
4.6 Stabilization of TauRDΔ oligomers by chemical cross-linking ........................ 54 
4.6.1 Separation of GA stabilized oligomers .................................................. 57 
4.6.2 Large scale purification of TauRDΔ oligomers by G200 column ............. 59 
4.6.3 Characterization of GA-stabilized oligomers purified by G200 column . 61 
4.6.4 Selection of the hydrophobic interaction chromatography column ........ 62 
4.7 In vitro Characterization of TauRDΔ oligomers .............................................. 65 
4.7.1 Large scale preparation of TauRDΔ oligomers ........................................ 65 
4.7.2 TauRDΔ oligomers undergo structural changes without ß-structure ....... 68 
4.7.3 Atomic force microscopy reveals globular TauRDΔ oligomers ................ 69 
4.7.4 Hydrodynamic radius of oligomers ........................................................ 71 
4.8 Functional characterization (extracellular effects) of TauRDΔ oligomers ....... 71 
4.8.1 TauRDΔ oligomers do not cause cell death in cell culture models .......... 72 
4.8.2 TauRDΔ oligomers do not cause cell death in OHSC model ................... 76 
4.8.3 Aggregation intermediates of full length Tau are not toxic .................... 77 
4.8.4 TauRDΔ oligomers cause loss of spines and postsynaptic proteins ....... 78 
4.8.5 TauRDΔ oligomers increase intracellular reactive oxygen levels ............ 80 
4.8.6 TauRDΔ oligomers increase intracellular calcium levels ......................... 82 
4.8.7 TauRDΔ oligomers do not cause phosphorylation and missorting of Tau 84 
4.8.8 TauRDΔ oligomers act as seeds for intracellular Tau aggregation .......... 85 




4.9.1 TauRDΔ oligomers aggregate into filaments after transfection into SH-
SY5Y cells ........................................................................................................ 87 
4.9.2 TauRDΔ oligomers recruit endogenous Tau into filaments ..................... 88 
4.9.3 TauRDΔ oligomers cause early apoptosis to the SH-SY5Y cells ............ 91 
5 Discussion ...................................................................................................... 93 
5.1 Stabilization and purification of TauRDΔ protein in vitro ................................. 94 
5.2 Structural properties of purified low-n TauRDΔ oligomers .............................. 96 
5.3 Functional properties of pro-aggregation TauRD oligomers ........................ 97 
5.3.1 Extracellular effects of TauRDΔ oligomers .............................................. 97 
5.3.2 TauRDΔ oligomers as intracellular seeds .............................................. 101 
6 References .................................................................................................... 106 
7 Publications .................................................................................................. 119 
Appendix ............................................................................................................... 120 
Acknowledgement ................................................................................................ 125 





°C – degree Celsius  
µg – micro gram 
µl – micro liter 
µm – micro meter 
µM – micro molar 
aa- amino acid 
AFM – Atomic Force Microscopy 
ANS – 8 anilino napthaleno sulfate  
APC - Allophycocyanin 
BCA – Bicinchoninic acid 
BSA – Bovine serum albumin 
Butyl FF – Butyl Fast Flow column 
CCD – Charged Coupled Device 
CD – Circular Dichroism 
CNS – Central Nervous System 
CV – Column Volume 
DLS – Dynamic Light Scattering 
DMEM – Dulbecco Minimal Essential Medium 
DMSO – Dimethyl Sulfoxide. 
DSS – Disuccinimidyl suberate 
DTT – Dithiothreitol 
E18 – Embryonic day 18 
EGCG – Epigallocatechin Gallate 
EM – Electron Microscope 
FCS – Fetal Calf Serum 
FTDP – Fronto Temporal Dementia linked with Parkinsonism 
GA – Glutaraldehyde 
GTO – Granular Tau Oligomers 
HBSS – Hank’s Balanced Salt Saline solution 
HCl – Hydrochloric Acid 
HIC – Hydrophobic Interaction Chromatography 
HPLC – High Performance Liquid Chromatography 




M – Molar 
mA – milli Ampere 
MAP – Microtubule Associated Proteins 
MBS - m-maleimidobenzoyl-N-hydroxysuccinimide ester 
mg – milli gram 
ml – milli liter 
mm – milli meter 
mM – milli molar 
MTBR – MicroTubule Binding Region 
MWCO – Molecular Weight Cut Off 
NaN3 – Sodium Azide 
NFT – Neuro Fibrillary Tangles 
ng – nano gram 
nm – nano meter 
nM – nano molar 
NMR – Nuclear Magnetic Resonance 
OD – Optical Density 
OHSC – Organotypic Hippocampal Slice Culture 
PAGE – Poly Acrylamide Gel Electrophoresis 
PBS – Phosphate Buffer Saline 
PDM - Phenylenedimaleimide 
PHF – Paired Helical Filaments 
PNS – Peripheral Nervous System 
PVDF – Poly Vinylidene DiFluoride 
Rpm – Rotations per minute 
RT – Room Temperature 
SDS – Sodium Dodecyl Sulfate 
SEC – Size Exclusion Chromatography 
TauRDΔ – Tau Repeat Domain protein with deletion of lysine at 280 position 
TauFL – Full length Tau protein 
TEA – Tri Ethanol Amine 
ThS – Thioflavin S 
V – Volt 





Tau protein is a microtubule associated protein present abundantly in the neurons of 
the central nervous system where it stabilizes the axonal microtubules thereby 
providing structural architecture for the axons of neurons. Aggregation of Tau occurs 
in many neurodegenerative diseases collectively termed tauopathies including 
Alzheimer disease (AD) and frontotemporal dementia (FTD). The mutation ΔK280 of 
Tau was originally discovered in cases of FTD (Rizzu et al., 1999). In vitro it leads to 
a pronounced propensity of the protein to aggregate (Barghorn et al., 2000). The 
repeat domain of Tau protein with this pro-aggregant mutation (TauRDΔ) induces 
toxicity in transgenic mice and organotypic hippocampal slice culture models (Sydow 
et al., 2011, Messing et al., 2013). One current concept of Tau-mediated toxicity in 
Alzheimer disease and related tau dependent pathologies is that it is based on low-n 
oligomeric species, rather than higher aggregated forms (fibers and neurofibrillary 
tangles). To test this we characterized oligomers from TauRDΔ protein assembled and 
purified in vitro. Since Tau oligomers are in dynamic equilibrium during aggregation, 
we tried to capture and stabilize only the oligomeric forms of Tau using EGCG 
(Epigallocatechin gallate). EGCG reduces the formation of fibrils and increases the 
SDS stable oligomers. However, the oligomers are not separable by gel filtration 
chromatography. Therefore we stabilized the tau oligomers using a low concentration 
of glutaraldehyde as a cross-linking reagent. This yielded SDS stable low-n oligomers 
predominantly in the form of dimers, trimers, tetramers with very low amounts of 
higher order species. The cross-linked TauRDΔ oligomers can be purified by 
hydrophobic interaction chromatography with ~95% purity. They exhibit enhanced 
fluorescence with the dye ANS, arguing for an altered conformation (compared with 
monomers) and possibly exposed hydrophobic surface patches. However, they do 
not contain substantial ß-sheet structure, as analyzed by thioflavin S fluorescence 
and circular dichroism. Atomic force microscopy (AFM) of TauRDΔ oligomers reveals 
that the particles are roughly globular in shape, with diameters in the range 1.6-5.4 
nm (AFM height values). The hydrodynamic radius of TauRDΔ oligomers (~5.2 nm) is 
dominated by that of tetramers, as measured by dynamic light scattering. The size of 
TauRDΔ oligomers reveals that they contain up to 4-5 molecules of Tau, consistent 
with the SDS gel analysis. The TauRDΔ oligomers do not exhibit global toxicity 
towards rat primary neurons when applied to the extracellular medium, as judged by 




pronounced (up to 50%) decrease of dendritic spines and a shift from  
mushroom-shaped to stubby spines. Consistent with this, the expression of 
cytoskeletal proteins which are necessary to maintain the mushroom spines is 
reduced. The neurons also show an increase in reactive oxygen species and influx of 
calcium. In summary, low-n oligomers of TauRDΔ do not cause gross changes in 
viability, but induce subtle functional defects, leading to an increase in Ca++ and 
ROS, and consequently to loss of spines and associated shape changes.  
Since Tau is an intracellular protein and the formation of oligomers occurs inside the 
cells, we introduced low-n Tau oligomers by protein transfection into SH-SY5Y cells 
and primary rat hippocampal neurons and analyzed them by flow cytometry and 
western blot analysis. This showed that only the cells transfected with TauRDΔ 
oligomers (but not monomers) induce the intracellular aggregation of Tau and 
recruitment of endogenous Tau into the aggregates. This is accompanied by the 
hyperphosphorylation of aggregated Tau. Although TauRDΔ oligomer transfected cells 
do not undergo cell death within 15 h of transfection, we found the presence of 
annexin V positive cells. When compared to monomers and fibrils, the oligomer 
transfected cells show a 5 fold increase in annexin V positive cells suggesting 
enhanced apoptosis. We conclude that TauRDΔ oligomers applied extracellularly 
cause degeneration of spines without affecting cell viability, whereas introducing 
oligomers intracellularly leads to Tau aggregation and apoptosis. 
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1.1 Neurodegenerative diseases 
Selective and progressive loss of structure and functions of neurons, including 
neuronal death is generally called neurodegeneration (Dickson et al., 2010). 
Neurodegeneration can be caused by genetic mutations in some neurodegenerative 
diseases, but more generally by a combination of causes related to advanced age 
(metabolic stress, failure of proteostasis, etc). Many neurodegenerative diseases are  
characterized by  the abnormal aggregation of misfolded proteins collectively called  
proteopathies. For example α-synuclein protein is aggregated in Parkinson disease, 
amyloid ß and Tau are aggregated in Alzheimer disease.  
1.2 Tauopathies 
Tau protein is a natively unfolded soluble protein primarily located on the 
microtubules of axons (Weingarten et al., 1974).  It stabilizes the microtubules 
thereby maintaining the structural architecture of the axons. Among the tauopathies 
characterized by aggregated tau, the best known disease is Alzheimer disease where 
the Tau protein is aggregated into neurofibrillary tangles within neurons. There are 
several other tauopathies like frontotemporal dementia (FTD), progressive 
supranuclear palsy (PSP) and traumatic brain encephalopathy (TBE) where Tau 
protein aggregates into filaments. In case of Pick disease and corticobasal 
neurodegeneration (CBD), the Tau protein accumulates into inclusion bodies rather 
than into neurofibrillary tangles (Arai et al., 2001). As of 2013, there were an 
estimated 44.4 million people with dementia worldwide. 50-75% of these are afflicted 
with AD (the most common neurodegenerative disease), 2/3 are women. This 
number will increase to an estimated ~75.6 million in 2030, and to 135.5 million in 
2050 (http://www.alz.co.uk/research/statistics). 
Alzheimer disease is characterized by selective loss of neurons and synapses 
(Morrison and Hof, 1997). The major hallmark of the disease is the presence of 
extracellular amyloid plaques containing fibrillar amyloid ß peptide (Glenner and 
Wong, 1984, Glenner et al., 1984, Masters et al., 1985), and neurofibrillary tangles 
consisting of hyperphosphorylated Tau protein (Grundke-Iqbal et al., 1986, Bancher 
et al., 1989). These histological findings were described in 1906 by the German 
psychiatrist Alois Alzheimer (Alzheimer, 1907). 
  Introduction 
2 
 
1.3 Tau and Alzheimer disease 
Tau protein is encoded by a single gene (MAPT) of >100kb long on human 
chromosome 17q21 (Neve et al., 1986). The Tau gene contains 16 exons. The 
promoter region of this gene lies in the exon1 of the gene. Exons 2, 3, and 10 
undergo alternative splicing to form the six main isoforms of Tau in the human CNS. 
Their ratio changes with brain development and in the various CNS compartments 
(Andreadis, 2006). 
1.3.1 Tau protein structure  
There are a variety of microtubule-associated proteins which vary between cell types 
and organisms. Some can be grouped together on the basis of their similar domain 
structure, such as the brain MAPs Tau and MAP2, and the ubiquitous MAP4, and 
there are several alternatively spliced isoforms whose expression is developmentally 
regulated (Cassimeris and Spittle, 2001).  
The longest isoform of Tau in the human central nervous system contains 441 amino 
acid residues. It can be subdivided into several domains (Gustke et al., 1994), 
roughly an N-terminal domain, a microtubule binding domain and C-terminal tail 
(Figure 1.2). The N-terminal half does not bind to microtubules, projects away from 
the microtubule surface, and hence is called "projection domain" Most of the C-
terminal half contributes to the interaction with microtubules,  facilitates their 
assembly and hence it is called assembly domain.  
The C-terminal half contains three or four semi-conserved repeated sequences of 31 
or 32 amino acids, termed R1, R2, R3 and R4. Repeat R2 corresponds to exon 10 
which can undergo alternative splicing. The N-terminal domain contains two inserts of 
29 amino acids each termed N1 and N2 which correspond to the alternatively spliced 
exon2 and 3. Thus the alternative splicing of exons 2, 3 and 10 leads to six splice 
forms of Tau of various lengths between 352 and 441 residues, termed 0N3R 
(smallest isoform) to 2N4R (largest isoform) (Figure 1.1) (Goedert and Jakes, 1990). 
In the peripheral nervous system there is an additional Tau isoform called “Big Tau” 
which contains additional 242 residues from exon 4a (Table 1.1)(Couchie et al., 
1992, Goedert et al., 1992).  
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Other mammalian organisms like mouse, rat, and cow have similar amino acid 
sequences of Tau with few variations, located mostly in the N-terminal domain. For 
example mouse Tau differs from human Tau only by 11 amino acids, ranging from 
341 to 430 amino acid residues (Lee et al., 1988). 




hTau40 2N4R 441 45.9 
hTau34 1N4R 412 43 
hTau24 0N4R 383 40 
hTau39 2N3R 410 42.6 
hTau37 1N3R 381 39.7 
hTau23 0N3R 352 36.7 
Big Tau 2N4R+ exon 4a 695 72.7 
Table 1.1 Isoforms of Tau 
hTau – Human Tau. The number designates the clone number. (Mandelkow and Mandelkow, 2012, 
Goedert and Jakes, 1990) 
 
Overall Tau has an unusually hydrophilic composition, consistent with its high 
solubility and natively unfolded structure. The N-terminal 120 residues are highly 
acidic (pI 3.8) followed by the basic proline-rich region (residues 150-240 residues, pI 
11.4), similar to the repeat domain (residues 240-368, pI 10.8) (Sergeant et al., 
2008). The proline-rich region contains numerous prolines, mainly in the form of SP 
(Ser-Pro) or TP (Thr-Pro) motifs. These motifs can be phosphorylated by proline-
directed kinases (such as MAP kinase, GSK3β, cdk5), and there are seven PXXP 
motifs which can form binding sites for proteins containing SH3 domains (Mandelkow 
and Mandelkow, 2012, Hanger et al., 2009). Figure 1.2 shows an overview of Tau 
domains, structural elements, and interaction partners (Mandelkow and Mandelkow, 
2012, Mukrasch et al., 2009). 
 




Figure 1.1 Tau structure and its isoforms 
A) Diagramatic representation of human Tau gene located at chromosome 17q21. The boxes are 
exons and the number denotes the exon numbers. The lines between the boxes are introns. B)  The 
primary mRNA transcribed from the Tau gene. C) There are 6 different isoforms of Tau with different 
chain lengths. Alternative splicing of exon 2 (Insert I1), 3(Insert I2) and 10 (R2) determines the length 
of the various isoforms. P1 and P2 = Proline rich region. aa = amino acids. Figure from S. Barghorn, 
PhD thesis, 2002. 
 
Tau protein is resistant to mild heat and acid treatment, which does not destroy its 
ability to interact with microtubules (Cleveland et al., 1977a). Biophysical studies 
showed that Tau protein is natively unfolded because of its hydrophilic nature 
(Gamblin, 2005, von Bergen et al., 2005, Jeganathan et al., 2008, Schweers et al., 
1994). Nuclear magnetic resonance spectroscopy and small angle X-ray scattering 
methods confirmed the natively unfolded conformation and dynamics of this protein 
with high resolution (Mukrasch et al., 2005, Shkumatov et al., 2011). Tau protein 
contains only a low content of secondary structure (α-helix and ß-strand) (Figure 1.2). 
This also opens the opportunity for other proteins to interact with Tau readily in the 
crowded environment of the cell. Due to its unfolded nature, the domains of Tau 
could also interact with themselves. An example is the paperclip conformation where 
the N-terminal and C-terminal domains of Tau interact with the repeat domain 
(Jeganathan et al., 2006). 
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1.3.2 Functions of Tau protein  
Tau protein was originally isolated as an interacting partner of microtubules 
(Cleveland et al., 1977b, Weingarten et al., 1974). Microtubules are assembled as 
polymers of α-ß-tubulin heterodimers. Microtubules have diverse tasks for example 
maintenance of the cytoskeleton architecture of a cell, separation of chromosomes 
during mitosis, or as tracks for intracellular transport by motor proteins. Tau promotes 
the assembly of microtubules and stabilizes them in neuronal axons; this interaction 
is based on the Tau repeat domain plus flanking regions (Mukrasch et al., 2005, 
Gustke et al., 1994). 
The microtubule assembly mediated by Tau can be modulated by its posttranslational 
modifications especially phosphorylation (Brandt et al., 2005). Two different types of 
kinases can phosphorylate Tau protein. The proline directed kinases target the SP 
and TP amino acid motifs. Examples are GSK3ß, CDK5, and MAPK. Other kinases 
 
Figure 1.2 Domains of Tau protein 
Representation of Tau structure deduced from NMR analysis. Most of the chain is unfolded (black 
lines), with a few short and transient elements of secondary structure (α-helix red, ß-strands yellow, 
poly proline helix green). The red box indicates the region of the two hexapeptide motifs responsible 
for Tau aggregation (von Bergen et al., 2000). The carboxy terminal half promotes microtubule 
assembly, and the amino-terminal half projects out from the microtubule surface. NI, N2 and R2 may 
be absent owing to alternative splicing. R1-R4 represents the repeat domain; together with the 
flanking domains, this represents the microtubule interaction domain. Bottom: Approximate location 
of interaction sites with other proteins. Figure adapted from (Mukrasch et al., 2009). 
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target KXGS motifs in Tau repeat domain which control the interaction with 
microtubules. For instance, phosphorylation at S262 strongly reduces the interaction 
of Tau with microtubules (Biernat et al., 1993). Figure 1.3 shows the kinases and the 
phosphorylation sites of Tau. 
 
Figure 1.3 Kinases and Phosphorylation sites of Tau 
This diagram shows the number of sites available for phosphorylation in Tau protein. The proline 
directed kinases are targeting the SP and TP amino acid sequences, whereas KXGS motifs are 
targeted by kinases like MARK. Figure adapted from (Schneider and Mandelkow, 2008). 
 
Detachment of Tau from microtubules by phosphorylation facilitates the attachment 
of motor proteins to walk on the microtubule track for intracellular transport (Trinczek 
et al., 1999). In addition to microtubules, Tau has numerous binding partners 
including signaling molecules and cytoskeletal proteins. Tau protein interacts with 
spectrin and actin filaments (Yu and Rasenick, 2006, He et al., 2009) which allows 
the Tau stabilized microtubule to interconnect with neurofilaments. This restricts the 
flexibility of microtubules (Farias et al., 2002). Tau as a scaffold protein modulates 
the activity of Src tyrosine kinases, c-Src and Fyn, and thereby facilitates c-Src-
mediated actin rearrangements (Figure 1.4) (Sharma et al., 2007). During the 
development of a neuron, Tau protein interacts with actin in a microtubule 
independent manner and promotes neurite outgrowth (Yu and Rasenick, 2006). In 
the nucleolar organizing region of the cell, Tau is thought to be involved in DNA 
repair and heat shock responses (Sultan et al., 2011). For reviews of Tau biology, 
see recent review by (Mandelkow and Mandelkow, 2012). 




Figure 1.4 Tau as a multi-functional protein. 
As a microtubule-associated protein, Tau contributes to microtubule dynamics and participates in 
neurite outgrowth and axonal transport. Moreover, Tau participates in cell signal transduction through 
the modulation of the activity of Src and Fyn kinases and PSD95 protein. In the nucleolar organizing 
region of the cell, Tau can also be involved in DNA repair and heat shock responses. Figure modified 
from (Mietelska-Porowska et al., 2014) 
1.3.3 Changes of Tau in Alzheimer disease 
In Alzheimer disease, Tau protein is thought to become detached from microtubules 
and loses its normal function of stabilizing microtubules. The free Tau molecules can 
become misfolded and interact with each other to form the filamentous structures 
(“paired helical filaments”) in the degenerating neurons (Hyman et al., 2005, Ghoshal 
et al., 2002, Garcia-Sierra et al., 2003). There has been a debate whether Tau is 
obligatory for disease or just a byproduct of some disease process. In case of 
Alzheimer disease the debate is still ongoing, as Tau is thought to be the mediator of 
Aß induced toxicity (Haass and Selkoe, 2007). However, it is now clear that Tau 
protein alone is sufficient to cause neurodegeneration and dementia, because 
mutations only in the TAU gene can cause the neurodegeneration and dementia in 
Fronto Temporal Dementia with Parkinsonism linked to choromosome-17 (FTDP-17) 
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(Goedert and Spillantini, 2001). Tau mutations have been found in progressive supra 
nuclear palsy (PSP), Pick disease (PiD) and other tauopathies. Increased expression 
of Tau protein alone can be a risk factor, as demonstrated by individuals carrying the 
H1c haplotype (Myers et al., 2007). These findings illustrate the causative role of Tau 
protein in neurodegenerative diseases. 
In Alzheimer disease and other Tauopathies, Tau protein undergoes several 
modifications including phosphorylation, acetylation, nitrosylation (Horiguchi et al., 
2003), oxidation (Schweers et al., 1995), ubiquitination (Cripps et al., 2006), 
glycosylation, glycation (Kuhla et al., 2007, Yan et al., 1994, Nacharaju et al., 1997), 
and proteolytic processing (Wang et al., 2007). These posttranslational modifications 
can disrupt the normal functions of Tau and may contribute to the formation of 
aggregates (Mandelkow and Mandelkow, 2012). However, it is not clear which of 
these post translational modifications are specific and necessary to cause the 
disease phenotype because many post translation modifications are present even 
under physiological condition. Aggregation of Tau is the most common modification in 
many Tauopathies including Alzheimer disease.  
1.3.4 Tau aggregation 
Although Tau is a highly hydrophilic and unfolded protein, it aggregates into well-
structured fibers in Alzheimer disease and other tauopathies. The mechanism of Tau 
aggregation is reasonably well understood from in vitro studies. Tau protein in 
solution is not able to aggregate because of its hydrophilic composition. In vitro 
aggregation is achieved by polyanionic cofactors like heparin or heparan sulfate 
which compensates the basic charge of the Tau (Goedert et al., 1996). Other 
polyanionic nucleation factors include nucleic acids (Kampers et al., 1996) , acidic 
lipid micelles, e.g. from arachidonic acid (Wilson and Binder, 1995) (Chirita et al., 
2003), acidic peptides resembling the C-terminus of tubulin (Friedhoff et al., 1998a) 
and carboxylated microbeads (Chirita et al., 2005) . 
Another important factor necessary for Tau aggregation is the ß propensity of       
hexapeptide motifs present in the beginning of repeat region R2 (VQIINK) and R3 
(VQIVYK) (von Bergen et al., 2000). Mutations (ΔK280 and P301L) in Tau protein 
increase the ß-propensity and accelerate the aggregation (von Bergen et al., 2001)  
(Figure 1.5). Tau aggregates have been analyzed in detail by various biophysical and 
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microscopic techniques which confirm the presence of ß-sheet structure (Barghorn et 
al., 2004, von Bergen et al., 2005, Mukrasch et al., 2005, Mukrasch et al., 2009) and 
twisted helical structure respectively (Figure 1.6). The core region of PHF is the 
repeat domain of Tau. The N-terminal and C-terminal regions spread away from the 
core structure and represent the fuzzy coat of PHF (Crowther and Wischik, 1985). 
This coat is still highly mobile even in the aggregated state (Sillen et al., 2005). This 
fuzzy coat has the characteristics of a “soft polymer brush” extending from the PHF 
core and is able to interact with other cellular components (Wegmann et al., 2013, 
Wegmann et al., 2010). 
 
Figure 1.5 Hexapeptide motifs and Tau aggregation pathway 
The longest isoform of Tau has 441 amino acids. Two hexapeptide motifs (275 VQIINK 280 and 306 
VQIVYK 311) are present at the beginning of repeat region R2 and R3 which are necessary for the ß-
sheet formation which is a core of the paired helical filaments. The bottom picture represents the 
formation of paired helical filaments. The post translation modifications detach the Tau molecules 
from microtubules and the free Tau molecule aggregates into oligomers and paired helical filaments. 








Figure 1.6 Paired helical filaments and NFTs 
A) Neurofibrillary tangles formed in neurons of Auguste D, drawn by Alzheimer. Figure from (Maurer 
et al., 1997) B) Electron micrograph of twisted fibers appearing as “paired helical filaments” isolated 
from Alzheimer brain tissue, with ~80 nm periodicity (arrowheads). C) Fibers assembled in vitro from 
the proaggregant Tau repeat domain (Tau
RDΔ
). Note the similarity of the twisted structures, even 
though the repeat domain contains only ~27% of the full-length protein. Figures B and C from 
(Mandelkow and Mandelkow, 2012). D) EM images of in vitro hTau40 fibril preparations show a 
heterogeneous mixture of fibril shapes. E) AFM topographs of the same fibril preparation confirm the 
heterogeneity of fibril structures but reveal details with superior contrast. Figures D and E from 
(Wegmann et al., 2010). 
 
1.3.4.1 Stages of Tau aggregation 
An important question in the field of proteinopathies is the mechanism of aggregation 
of a protein. Tau aggregates like PHFs (fibers) and NFTs (assemblies of fibers) are 
formed by successive aggregation of monomers and/or smaller soluble oligomers 
(Cowan and Mudher, 2013). Partially folded Tau monomer favors the spontaneous 
formation of dimers (Chirita et al., 2005). Dimers are the important intermediate 
species which control the rate of aggregation (Schweers et al., 1995, Wille et al., 
1992). Consistent with this, the in vitro generated Tau dimers form larger oligomers 
and aggregates (Sahara et al., 2007, Patterson et al., 2011). Apart from dimers,  
low-n oligomers such as trimers and tetramers are also involved in the formation of 
polymers or Tau filaments(Lasagna-Reeves et al., 2010).  
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Many sporadic Tauopathies have mutations in the MAPT gene. Several mouse 
models with mutations in the Tau gene have been created to understand the 
aggregation process in vivo. Expression of human Tau isoforms with or without 
mutations cause a neurodegenerative disease phenotype proving the role of Tau in 
memory impairment and neuronal loss (Ramalho et al., 2008, Yoshiyama et al., 
2007, Santacruz et al., 2005, Mocanu et al., 2008, Sydow et al., 2011, Eckermann et 
al., 2007). Most of these mutations are in or near the repeat domain of Tau. These 
mutations tend to weaken the binding of Tau to microtubules and enhance the 
aggregation of Tau (Brunden et al., 2009, Combs and Gamblin, 2012). Mutations in 
the Tau genes are represented in Figure 1.7.The list of the mutations of Tau can be 
found in www.alzforum.org. 
 
Figure 1.7 Mutations of tau gene 
This diagram represents the sites of Tau which are mutated in frontotemporal dementia with 
parkinsonism. Exons 9,10,11,12 and 13 of repeat domain of Tau have many mutations. However, the 
N-terminal and proline rich regions also have some mutations. Figure adapted from (Schneider and 
Mandelkow, 2008). 
 
1.3.5 Toxicity of Tau aggregates 
A major concern in the field of tauopathies is the mechanism of toxicity of Tau. The 
supporting and opposing arguments for the toxicity of different forms of Tau 
summarized below. 
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1.3.5.1 Toxicity of NFTs 
In Alzheimer disease and other Tauopathies, cognitive decline and neuronal loss are 
well correlated with the presence of NFTs (Tomlinson et al., 1970, Braak and Braak, 
1991b, Arriagada et al., 1992, Dickson et al., 1995, Nagy et al., 1995). The formation 
of NFTs and the loss of neurons are observed in parallel in the same regions of the 
brains of AD mouse models. For example, expression of P301L mutant Tau in the 
mouse under the Thy 1.2 promoter causes neuronal apoptosis and formation of NFTs 
in the same location (Gotz et al., 2001). More direct evidence emerged from mouse 
and C elegans models expressing both pro-aggregant (promotes ß-structure 
formation) and anti-aggregant (does not form ß-structure) mutant forms of Tau. 
Expression of the pro-aggregant TauRDΔ mutant in the mouse brain evokes neuronal 
loss and NFT formation in the CA3 region of the hippocampus (Mocanu et al., 2008).  
When the expression of the pro-aggregant Tau (TauRDΔ) is switched off in the mouse 
model, the toxic effects were reversible including memory decline (Sydow et al., 
2011).  By contrast expression of anti-aggregant Tau (TauRDΔ-PP) does not cause 
memory decline in transgenic mice. Similarly, pro-aggregant TauRDΔ expression in 
worms also leads to aggregation and synapse loss, but treating the pro-aggregant 
worms with certain aggregation inhibitors rescues the toxic effects (Fatouros et al., 
2012). In several Drosophila models of AD and Tauopathies, expression of human 
Tau leads to neurodegeneration without the formation of NFTs (Williams et al., 2000, 
Wittmann et al., 2001, Mudher et al., 2004). Similarly, mouse models expressing non 
mutant human Tau do form NFTs, but the cognitive deficits occur much earlier than 
NFT formation (Andorfer et al., 2005). In case of two inducible mouse models, 
expressing either full length Tau-ΔK280 mutation (Eckermann et al., 2007) or P301L 
(Spires et al., 2006), switching off the expression of mutant Tau after the NFT 
formation and cognitive decline rescues the memory, stabilizes the cell loss yet NFTs 
remain.  These evidences suggest that NFTs or PHFs do not cause toxicity and imply 
that there are smaller species of Tau which might be necessary for Tau related 
toxicity..  
1.3.5.2 Toxicity of insoluble Tau oligomers 
As NFTs or PHFs may not be the toxic species, the focus shifted to the species 
preceding the filaments. Earlier it was shown that soluble Tau is not toxic in an 
inducible cell model. However, cells expressing pro-aggregant mutant Tau died even 
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before the NFT formation (Khlistunova et al., 2006) which suggest that there is an 
intermediate species of aggregation which could be toxic, such as higher-n oligomers 
(pre aggregated oligomers). Insoluble oligomers occur also in the synaptosome 
fractions of AD brain which impair the ubiquitin proteasome system (Tai et al., 2012). 
These findings suggest that insoluble oligomers are toxic.  
1.3.6 Small soluble Tau oligomers 
The terminology and definition for Tau oligomers is not yet well defined. Thus, 
molecules as small as dimers and up to prefibrillar forms of Tau are collectively called 
Tau oligomers. The in vitro prepared Tau oligomers are formed from non-
phosphorylated Tau monomers. But in the case of AD, Tau oligomers mostly consist 
of hyperphosphorylated Tau. Methods like electron microscopy, atomic force 
microscopy and pelleting assays allow one to determine the different stages of Tau 
aggregation as follows. 
 Low-n oligomers (<10 mers) are visible on SDS gels after pelleting, and can 
be seen in the AFM, but not by EM.These species are soluble. 
 There are larger oligomers usually visible as blobs by EM. These are really 
polymers (hundreds of subunits), which one could consider as granular Tau 
oligomers. 
 Insoluble Tau oligomers obtained by pelleting assay consist >70 subunits. By 
contrast, even fairly high-n oligomers (>10 but <70) are still “soluble” by 
pelleting criterion but can be distinguished from low-n oligomers by AFM. 
1.3.6.1 Formation of Tau oligomers in vitro 
Several groups studied Tau oligomerization in vitro. The 3R construct (K12) readily 
forms dimers in non-reducing conditions. Cross-linking of 3R tau protein with PDM 
and MBS yielded dimers and oligomers. The authors also showed that the dimers 
formed are in anti-parallel orientations (Wille et al., 1992). Oxidation of Cys 322 in 3R 
tau constructs (K12) lead to the formation of dimers, trimers and higher order 
oligomers. The C322A mutant of the Tau-K12 construct did not form filaments 
suggesting the importance of Cys 322 in aggregation (Schweers et al., 1995). Other 
authors showed that two distinct Tau dimers could be generated in vitro in the 
presence of heparin 6,000. These dimers are either Cysteine dependent or 
independent. Cysteine dependent dimers were observed before the increase in the 
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ThT fluorescence signal. Hence they suggest that intermolecular disulfide cross-
linking mediated by the PHF6 hexapeptide facilitates the Tau oligomerization (Sahara 
et al., 2007).  
The aggregation of Tau could be monitored in real time using the ThS or ThT dye 
which detects the ß-sheet structure in the aggregates (Friedhoff et al., 1998a). The ß-
sheet content increases with aggregate size. The higher rate of ß-sheet structure 
occurs after the formation of oligomers comprised of 8-14 monomers as they act as 
nucleation seeds for PHFs (Friedhoff et al., 1998b). Full length Tau constructs with 
the deletion of the hexapeptide motif PHF6 (306-VQIVYK-311) sequence formed only 
dimers and trimers after prolonged incubation with heparin which shows that this 
sequence is important for the formation of oligomers and aggregates. This construct 
could also form some aggregates (without pronounced ß-sheet structure), but do not 
form filamentous structures when analyzed by AFM (Sahara et al., 2007). These 
results indicate that intermolecular disulfide crosslinking along with PHF6 
hexapeptide facilitates tau oligomerization and aggregation.  
Mutations in the Tau gene found in frontotemporal dementias are known to 
accelerate the neurodegeneration. An example is the deletion mutation of lysine 280 
of Tau which promotes ß-sheet formation, rapid aggregation (von Bergen et al., 
2000) and toxicity, presumably through oligomers (Khlistunova et al., 2006, Kumar et 
al., 2014, Mocanu et al., 2008, Sydow et al., 2011).  
1.3.6.2 Toxicity of soluble Tau oligomers  
Formerly it was thought that neuronal loss and cognitive impairment was caused by 
NFTs whose distribution was well correlated with disease progression (Arriagada et 
al., 1992, Braak and Braak, 1991b, Gomez-Isla et al., 1997), but more recent 
evidences shifted the emphasis to Tau oligomers. Neurodegeneration can occur 
even before the NFT formation, and in certain mouse lines expressing human Tau 
the NFTs do not correlate well with neuronal loss (Andorfer et al., 2003). Another 
mouse model expressing P301L Tau, showed synapse loss and microgliosis even 
before the NFT formation (Yoshiyama et al., 2007). An inducible mouse model 
expressing full length human Tau with the ΔK280 mutation (pro-aggregant), even at 
low expression level causes Tau hyperphosphorylation, missorting, microgliosis, 
astrocytosis, synapse loss, pathological conformation by MC1 antibody, but no tangle 
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formation or neuronal loss. Still this mouse shows strong cognitive decline. Switching 
off the expression of the human Tau recovered the synapse loss, LTP and memory 
(Van der Jeugd et al., 2012).   
In order to validate the oligomer hypothesis, several groups have purified the full 
length tau oligomers in vitro and also from AD brains. The toxic effects of these Tau 
oligomers prepared by cross-seeding with Aß were analyzed in both cell and animal 
systems.   In vitro prepared SDS stable dimers and trimers reduced the cell viability 
in SH-SY5Y cells up to 80%, neuronal loss in mouse hippocampus (Tau oligomers 
injected), whereas monomers and fibrils did not compromise the cell viability and 
neuronal loss (Lasagna-Reeves et al., 2010, Lasagna-Reeves et al., 2011).  
Some laboratories generated antibodies against Tau oligomers to characterize 
oligomers and to use them for staging or treating AD. Using these antibodies (T22 
and TOMA), Kayed and coworkers found that Tau oligomers are present in AD and 
other neurodegenerative diseases. These authors observed that there is a rapid 
accumulation of Tau oligomers in the rat model of traumatic brain injury (Hawkins et 
al., 2013) . Increased Tau oligomers were also observed in progressive supranuclear 
palsy patients(Gerson et al., 2014), consistent with patients carrying the Tau-A152T 
mutation, as risk factor for PSP (Coppola et al., 2012) . Other Tau oligomers specific 
antibody includes TOC1 antibody which recognize the pre-fibrillar Tau aggregates 
and used as a tool in assessing the disease progression (Patterson et al., 2011, 
Ward et al., 2013). 
1.4 Inhibition of Tau aggregation  
Given that the ability of Tau to aggregate is considered to be detrimental to neurons 
one may expect that Tau aggregation inhibitors could be protective. Therefore 
several groups searched for aggregation inhibitors (Bulic et al., 2009, Brunden et al., 
2009, Schafer et al., 2013, Wischik et al., 2014, Wobst et al., 2015). Indeed beneficial 
effect could be shown in several cell and animal models.  Members of different 
substance classes, such as antraquinones, N-phenyl amines, 
phenylthiazolhydrazides and rhodanines can inhibit Tau aggregation and also 
disassemble existing filaments (Pickhardt et al., 2005). For example bb14, a 
rhodanine based Tau aggregation inhibitor inhibits the aggregation of Tau in 
organotypic hippocampal slice culture expressing pro-aggregant TauRDΔ. bb14 
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treated slices showed improvement in LTP and prevent the calcium dysregulation 
and synapse loss (Messing et al., 2013). Similarly, B4D3, D1C11 and B4A1 was 
shown to inhibit the aggregation of Tau and also to disassemble preformed 
aggregates (Khlistunova et al., 2006). Phenothiazines such as methylene blue inhibit 
Tau aggregation as well as oligomerization of Aß. Methylene blue is neuroprotective 
by inhibiting the aggregation of Tau (Hochgrafe et al., 2015, Schirmer et al., 2011, 
Lira-De Leon et al., 2013) and by inhibiting the reactive oxygen species production 
(Begum et al., 2008). Another compound (cmp-16) is shown to inhibit aggregation of 
Tau in C elegans models of Tauopathy (Fatouros et al., 2012). Although these 
compounds inhibit aggregation, it is not clear whether they also clear the Tau 
oligomers. Recently, it has been shown that curcumin is able to suppress soluble Tau 
dimers, there by rescuing the synaptic and behavioral deficits (Ma et al., 2013). 
Another compound, polyphenol epigallocatechin gallate (EGCG) efficiently inhibits 
the fibrillogenesis of both α-synuclein and amyloid ß. The mechanism is that EGCG 
directly binds to the natively unfolded polypeptides and prevents their conversion into 
toxic, on-pathway aggregation intermediates and reduces cellular toxicity (Bieschke 
et al., 2010) (Ehrnhoefer et al., 2008). EGCG coated nanoparticles are efficient in 
reducing the amyloid beta aggregation and the cell toxicity. (Zhang et al., 2014). 
Similarly, the Tau aggregation inhibitors might also induce the formation of off-
pathway oligomers. These observations show that it is important to target Tau 
oligomers by different approaches in order to find a cure against the toxic species of 
Tau.  
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2 Aims of the study: 
The aims of the project were to develop procedures for the purification of oligomers 
of TauRDΔ protein, characterize their biochemical and biophysical properties, and test 
their ability to induce toxicity in neurons. 
The following problems were investigated in detail: 
1. In vitro characterization of TauRDΔ protein aggregation to understand the 
stages of aggregation 
2. Stabilization oligomers of TauRDΔ by different methods and characterization of 
the oligomers formed 
3. Development of methods to prepare and purify oligomers of TauRDΔin vitro 
4. Biophysical and biochemical characterization of in vitro purified oligomers of 
TauRDΔ 
5. Structural characterization of TauRDΔ oligomers using microscopy and dynamic 
light scattering methods 
6. Functional characterization of TauRDΔ oligomers in cell culture models using 
different types of assays 
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3 Materials and Methods 
3.1 Materials (Instruments and equipment) 
3.1.1 Centrifuges 
Name Company 
Eppendorf centrifuge 5415C Eppendorf, Hamburg 
Eppendorf centrifuge 5810R Eppendorf, Hamburg 
Eppendorf centrifuge 5810 Eppendorf, Hamburg 
OptimaTM LE-80K Ultracentrifuge Beckman Coulter, München 
AvantiRCentrifuge J-26 XP Beckman Coulter, München 
OptimaTM Max Ultracentrifuge Beckman Coulter, München 
3.1.2 HPLC 
Name Company 
Äkta micro system GE Healthcare Life Sciences, Freiburg 
Äkta explorer100 GE Healthcare Life Sciences, Freiburg 
3.1.3 Columns  
Name Company 
Superose PC12 (3.2mm x 300mm) Amersham Biosciences, Freiburg 
Superdex G200 HR 16/60 Amersham Biosciences, Freiburg 
Superdex G75 HR 16/60 Amersham Biosciences, Freiburg 
Superdex peptide Amersham Biosciences, Freiburg 
SP Sepharose 16/10 Amersham Biosciences, Freiburg 
HiTrap HIC Selection Kit GE Healthcare Life Sciences, Freiburg 
HiPrep Butyl FF 16/10 GE Healthcare Life Sciences, Freiburg 
PD 10 column  GE Healthcare Life Sciences, Freiburg 
NAP5 column Pharmacia Biotech 
HiTrap NHS-activated HP 1ml  GE Healthcare Life Sciences, Freiburg 
3.1.4 Spectrophotometers 
Name Company 
Ultrospec 3100 pro  Amersham Biosciences, Freiburg 
Tecan Spectrophotometer  Lab System, Frankfurt 
Spex Fluoromax spectrophotometer   Polytec, Waldbronn 
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Dynamic Light Scattering Nano S MALVERN, Germany 
Jasco J-810 CD spectrometer   Jasco, Gross-Umstadt 
3.1.5 Microscopes 
Name Company 
Electron Microscope JEOL 
Atomic Force Microscope (Dimension 
model 3100)  
Veeco 
Olympus CK2 microscope   Olympus, Japan 
LSM 700 Confocal Microscope  Zeiss 
Cell observer Zeiss  
Lambda 10-2 (Shutter for calcium 
imaging)  
Visitron Systems 
Dissection microscope Olympus SZX9 
3.1.6 Cell culture equipment 
Name Company 
HERA Safe Laminar air flow Heraeus Instruments, Germany 
HER Cell 240 CO2Incubator Heraeus Instruments, Germany 
Preparation laminar air flow Thermo Scientific 
Tissue Chopper Mickle Laboratory Engineering co.ltd 
Light source KL 1500 LED Schott  
Neubauer chamber   MARIENFELD, Germany 
HERA Safe Laminar air flow Heraeus Instruments, Germany 
HER Cell 240 CO2Incubator Heraeus Instruments, Germany 
3.1.7 Others 
Name Company 
French Press G-Heinemann Ultraschall und 
labrotechnik 
Ice flaking machine (SPR 80)  Nord Cap 
Water filtration apparatus  Millipore 
Deep freezer (-80°C) SANYO 
Image Quant LAS 4000 mini GE Healthcare Life Sciences, Freiburg 
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Blotting Apparatus BIO-RAD trans-blot SD transfer cell 
Gel apparatus for SDS-PAGE SE 250, Hoefer 
Electrophoresis power supply Pharmacia Biotech 




Weighing balance BP 310S Sartorius 
Incubators Memmert 
Incubator with shaker INFORS HT Multitron 
Heating-agitator Eppendorf 
Incubator with rotator Shake and Stack, HYBAID 
Laminar flow for bacterial inoculation LaminAir HB 2448, Heraeus Instruments 
pH-Meter Schott Instruments 
Water bath GFL AND JULABO UC 
Vortexer JANKE & KUNKEL. IKA-WERK 
Pasteur pipette Assistant 
well plates (6,12,24,48, and 96) Corning 
SNL 10 cantilever  Bruker, München 
Glass wares VWR international 
PVDF membrane (0.45µm pore size),   Millipore transfer membrane 
Quartz microcuvettes Hellma, Muhlheim, Germany 
Magnetic steel disks (diameter 12mm) Ted Pella, Inc., Redding, 
CA, USA 
Teflon sheets (0.2 mm thickness) Maag Technic AG, 
Birsfelden, Switzerland 
Mica sheets Muscovite, Kolkatta, India 
Cantilever (Si3N4) Di-Veeco, Santa 
Barbara, California, USA 
3.1.8 Chemicals 
Chemicals of highest quality were purchased from the following suppliers: 
Sigma, Merck, Gerbu, Amersham Pharmacia Biotech, AppliChem, Molecular Probes, 
Fluka, Serva 




Note: The buffer compositions are listed in the appendix section. 
3.2.1 Protein preparation and purification 
100 ml of LB broth was prepared and autoclaved. The antibiotic carbenecillin 
(50µg/ml) was added to the broth. The glycerol stock of TauRDΔ BL21 (DE3) was 
inoculated by taking a pinch at the end of pipette tip. This pre-culture was grown at 
37°C at 180rpm in a shaker incubator overnight. 2 liters of “terrific broth” was 
prepared and autoclaved. The antibiotic ampicillin (100mg/l) was added to the terrific 
broth. 100ml of pre-culture was inoculated to the fresh 2 liters of terrific broth. Before 
inoculating, 2ml of terrific broth was used for optical density (OD) measurement as 0 
time point control. The inoculated culture was grown at 37°C with 180rpm rotation 
until the OD reached a minimum of 0.8 (approximately 4 h) as determined 
photometrically at 600 nm (Ultrospec 3100 pro, Amersham Biosciences, Freiburg) at 
600nm. The sample was induced by IPTG to a final concentration of 0.4mM for 3 h. 
The culture was pelleted by centrifuging at 7000 rpm for 12 min (JLA-8.1000 rotor, 
AvantiRCentrifuge J-26 XP, Beckman Coulter, München). The pellet was collected in 
90 ml of resuspension buffer and mixed at 4°C by magnetic stirring. (The cells can be 
frozen at this stage for later usage. The cells should be defrosted slowly in water). 
The resuspended pellet was homogenized using a French press. This 
homogenization was repeated once more to completely break down the cell wall, 
DNA and other cell components. The homogenized cells were collected in 50ml 
Falcon tubes. NaCl and DTT were added at a final concentration of 500mM and 5mM 
respectively. This sample was mixed well and boiled at 97°C for 20 min. The 
temperature was maintained carefully throughout the boiling step. (Note: The lid of 
the Falcon tube should be opened slowly during boiling and then closed again). The 
solution was mixed well, then ultracentrifuged (Ti 45 rotor) at 40,000 rpm, for 1 h at 
4°C (OptimaTM LE-80K Ultracentrifuge, Beckman Coulter, München). The 
supernatant was collected and dialyzed with a 45kDa MWCO membrane. The 
supernatant was dialyzed twice in Mono S A buffer with a single exchange of buffer 
at 4°C. One round of dialysis was done overnight. (Note: The volume of dialysis 
buffer should be at least 10 times higher than the sample volume). The dialyzed 
supernatant was centrifuged (Ti 45 rotor) at 40,000 rpm, for 1 h at 4°C. The 
supernatant was removed and added to the 150ml super loop for purification. (Note: 
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Air bubbles must be avoided when filling in the super loop). The protein was purified 
by anion exchange chromatography using the Äkta Explorer100 (GE Healthcare Life 
Sciences, Freiburg) system fitted with a SP Sepharose 16/10 column (Amersham 
Biosciences, Freiburg). The column was equilibrated with 5 column volumes (CV) of 
Mono S A buffer. Once the sample was injected, the purified protein was eluted with 
Mono S A and Mono S B buffer in a gradient segment (Mono S B 60% gradient for 
5CV and 100% gradient for 1CV). The column was cleaned with Mono S B buffer for 
4CV. The purified protein was eluted in 2ml fraction volume. The fractions were run 
on a 17% SDS gel and stained with Coomassie Blue. The protein containing fractions 
were pooled and concentrated using 3000 MWCO centrifugal filters (Amicon Ultra, 
Millipore, Ireland). Then the protein was further purified by gel filtration 
chromatography using a Superdex G75 column in the Äkta Explorer 100. PBS pH 7.4 
with 1mM DTT was used as a mobile phase.  The eluted protein was concentrated 
using 3kDa MWCO amicon filters and then the protein concentration was measured 
using the BCA method.     
3.2.2 Determination of protein concentration (BCA assay) 
The BCA method (BCA protein assay reagent, Sigma) was used to determine the 
concentrations of proteins. A standard curve was prepared using BSA at different 
concentrations (40 -200µg/ml). The protein sample and standard sample were diluted 
in 50µl of H2O and mixed with 1 ml of reagent mixture consisting of  1 ml copper (II) 
sulfate (Sigma) 4% (w/v) and 50 ml biocinchoninic acid solution (Sigma). The mixture 
was incubated at 60°C for 30 min, and the absorption was measured at 562 nm in a 
spectrophotometer (Ultrospec 3100 Pro Pharmachia Biotech). For the blank 
reference, H2O was used instead of the protein solution.. 
3.2.3 Aggregation of TauRDΔ 
3.2.3.1 Polymerization (into filaments) of TauRDΔ 
For preparation of fibrils, TauRDΔ monomer was diluted to 50 µM in PBS pH 7.4 or in 
TBS pH 9.0 supplemented with 1mM DTT and heated at 95°C for 15 min in order to 
disrupt disulfide cross-links. Then the sample was brought to room temperature. This 
monomer solution was incubated at 37°C for different time intervals (0, 0.5, 1, 2, 4, 8, 
24, 48 and 72 h) for the aggregation kinetics assay. For EGCG experiments, EGCG 
was added prior to the incubation. The formation of aggregates was monitored by 
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ThS fluorescence and the morphology of filaments was analyzed by electron 
microscopy. 
3.2.3.2 Oligomerization of TauRDΔ 
50µM TauRDΔ monomer was incubated in either PBS pH 7.4 or in TBS pH 9.0 for 30 
min at 37°C without DTT. (Since DTT breaks disulfide cross-links, we omitted it in 
order to avoid disassembly of formed oligomers). The aggregated samples 
(oligomers) were cross-linked using 0.01% glutaraldehyde (EM grade) for 10 min at 
37°C. The reaction was stopped by final addition of 10mM Tris-Cl, pH 8.8. 
3.2.3.3 Sedimentation assay  
The aggregated samples of TauRDΔ (72 h of incubation; concentration 50µM in 
phosphate buffer pH 7.4 in the presence or absence of EGCG) were centrifuged at 
61000 rpm (TLA 100.3) for 1 h at 4°C to generate a pellet fraction of aggregated Tau 
protein. After centrifugation, the supernatant and pellet was separated. The pellet 
was resuspended in the same volume as the supernatant. The SDS sample buffer 
was added to pellets and supernatants, followed by heating at 95°C for 10 min. The 
samples were run on a 17% SDS-PAGE gel and the amount of Tau protein in the 
supernatants and pellets were quantified by densitometry of the Coomassie Brilliant 
Blue R-250 stained gels using Image J analysis software (Schneider et al., 2012). 
3.2.3.4 SDS gel analysis 
The samples (fractions from HPLC, pelleting assay, cell lysates, brain homogenates) 
were mixed with 1X sample buffer and heated at 95°C for 15 min. Then samples 
were run on 17% SDS gel at constant 120V for 2 h at room temperature. For the 
primary neuronal cell lysates, the samples were run on 10% SDS gel at 120V for 1.5 
h at room temperature. The gels were stained with Coomassie and silver in case of in 
vitro samples. The brain homogenate samples were run and transferred to a PVDF 
membrane for western blot analysis. 
3.2.3.5 Coomassie staining 
An SDS gel was transferred to the Coomassie stain solution for 30 min to 1 h. The 
gel was then transferred to the destaining solution (intensive) for another one h. If 
normal destaining solution was used then the gel was left overnight. All these steps 
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were done at room temperature on a shaker. Afterwards the gel was scanned and 
used for analysis. 
3.2.3.6 Silver staining 
The SDS gel was transferred to fixative solution and incubated for 15 min then 
transferred to cross-linking solution and incubated for 30 min up to overnight. The 
gels were washed with doubly distilled water three times for 10 min each. Then the 
gels were incubated with silver nitrate staining solution for 20 min. Then the gels 
were briefly washed with doubly distilled water for 30 seconds. The developing 
solution was added to the gels after discarding the water. After the detection the 
stopping reagent was added immediately to avoid further development. All these 
steps were done on the shaker at room temperature.  
3.2.3.7 Western blotting 
The SDS gels were incubated in 50ml of 1X transfer buffer for 15-20 min at RT. Then 
3 pieces of wet Whatman filter papers were placed in the transfer apparatus plus a 
single PVDF membrane. The PVDF membrane was activated by soaking it in 
methanol for 1 minute and then washing in transfer buffer thoroughly. The gel was 
placed on the PVDF membrane. Another 3 pieces of Whatman filter paper were 
placed on the gel. The transfer was started at 100mA (for a gel area of 67.5 cm2 i.e. 
1.5 mA per cm2) for 2 h (depending on the molecular weight of the protein to be 
analyzed). The transfer was checked by prestained markers on the blot. The blot was 
incubated with 5% fat dry milk powder in TBST for 1 h at RT on a shaker and 
incubated with primary antibody overnight at 4°C. Unbound antibodies were washed 
with 1X TBST, 3 times, 10 min each. The secondary antibody was added to the blot 
and incubated at 37°C for 1 h and then the unbound antibodies were washed away 
using 1X TBST (3 times, 10 min each). Finally, the membrane was developed using 
the ECL reagent kit and the images were acquired using LAS ImageQuant 
application software developed by GE Healthcare. 
3.2.4 Separation of oligomers of TauRDΔ  
3.2.4.1 Size exclusion chromatography (Superose PC12 column) 
Size-exclusion chromatography (SEC) is a chromatographic method in which 
molecules in solution are separated by their size, and molecular weight. The columns 
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have a matrix with a particular pore size. The molecules run on SEC column will 
travel through the whole matrix. The larger molecule will not travel through all the 
pores thereby elute earlier whereas the smaller molecule will pass through all the 
pores and elutes later.  
A sample of TauRDΔ oligomers formed in PBS buffer, pH 7.4 was used to standardize 
the separation of oligomers from the monomers. An analytical Superose PC 12 
column was used. The column was pre equilibrated with elution buffer (PBS pH 7.4) 
for 10X column volume (CV) and calibrated with the standard proteins. Approximately 
50-100µl sample of oligomers containing solution of TauRDΔ was injected in to the 
ÄKTA micro system fitted with the Superose PC 12 column. If stable oligomers are 
present, they will elute earlier than the monomer in the chromatogram. The system 
was run at 40 -100µl/min flow rate and the elution was monitored at 214, 252 and 
280nm. The fractions were collected in 96 well plates. The column was washed with 
distilled water for 5 CV and re equilibrated with 5 CV of elution buffer. The protein 
fractions were run on 17% SDS gel to analyze the quality of separation.  
3.2.4.2 Large scale preparation using a Superdex G-200 column 
The column was pre equilibrated with elution buffer (2x column volume (CV)) and 
calibrated with the standard proteins. For separation of TauRDΔ oligomers an ÄKTA 
explorer 100 system was used. 2 ml of a solution containing oligomers of TauRDΔ was 
injected into Superdex G-200 column and run at 0.5-1ml /min flow rate. The elution 
was monitored at 214, 252 and 280nm. The fractions were collected in 2ml volumes. 
The column was washed with the distilled water (2x CV) and re equilibrated with 2x 
CV of elution buffer. The protein fractions were run on 17% SDS gels to analyze the 
quality of separation.  
3.2.4.3 Hydrophobic interaction chromatography (HIC) 
The cross-linked TauRDΔ oligomers were separated on a HIC column. For 
standardizing the purification method, the HIC selection kit from GE Healthcare was 
used. 1M ammonium sulphate was used as adsorption buffer. The elution buffers 
were TBS pH 9.0 or PBS pH 7.4 and doubly distilled water. All HiTrap 1ml HIC 
columns were equilibrated with adsorption buffer (10x column volume) before 
injecting the sample (300µl – 900µl). The hydrophilic proteins do not bind to the 
column (unbound protein) and were collected as flow-through. The bound 
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hydrophobic proteins were eluted in an TBS pH 9.0 and water. The eluted fractions 
were run on 17% SDS gel and the separation was checked by staining the gels with 
silver. 
A Butyl FF column 16/10 was used for further large scale purification. The column 
was pre equilibrated with adsorption buffer (3-5x CV) and then the samples (1.8ml) 
were injected into the column. Unbound proteins were collected as flow-through. The 
bound proteins were eluted as fractions of 2-3ml with a gradient of doubly distilled 
water with TBS pH 9.0. The fractions were run on the SDS gels and then the quality 
was confirmed by silver staining.  
The fractions containing pure oligomers were pooled together and concentrated 
using 3kDa MWCO Amicon filters at 4000 rpm for 1.5 – 2 h at 4°C. These 
concentrated oligomers were transferred to PBS pH 7.4 buffer using PD 10 buffer 
exchange column.  The PD 10 column was equilibrated with 5ml elution buffer (PBS 
pH 7.4). This equilibration step was repeated 4 times. Then 2.5 ml of pooled protein 
fractions were loaded on top of the bed. If the initial volume of the sample was 
smaller it was topped up with PBS to 2.5ml. The flow-through was collected for 
further analysis. Then the protein was eluted in 3.5ml of PBS. The column was never 
allowed to dry during the procedure. Protein estimation was done by BCA method. 
3.2.5 Biophysical methods 
3.2.5.1 Thioflavin S (ThS) assay 
The formation of filamentous polymers of TauRDΔ was monitored by the ThS 
fluorescence assay (Friedhoff et al., 1998b). The binding and subsequent increase in 
ThS fluorescence is specific for the cross ß-structure that is typical of amyloid fibers. 
5 µM final concentration of the PHF reaction mixture was mixed with PBS pH 7.4 or 
ammonium acetate buffer, pH 7.0 containing 20 µM ThS and transferred into a 384-
well plate (black microtiter 384 plate round well, ThermoLabsystems, Dreieich).  The 
measurements were carried out at 25˚C in a TECAN spectrofluorimeter (Ascent, Lab 
systems, Frankfurt) using an excitation wavelength of 440 nm, an emission 
wavelength of 521 nm and spectral bandwidths of 2.5 and 2.5 nm for emission and 
excitation respectively. Background fluorescence from ThS alone was subtracted 
when needed and the measurements were carried out in triplicates always. 
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3.2.5.2 ANS fluorescence measurement 
The formation of polymers of TauRDΔ  was also monitored by ANS fluorescence which 
increases when the dye binds to solvent exposed hydrophobic patches and positively 
charged amino acids (Slavik, 1982). 5µM final concentration of PHF reaction mixture 
was mixed with 45 µl of 50 mM ammonium acetate pH 7.0 containing 20µM ANS and 
transferred into a 384-well plate (black micro titer 384 plate round well, 
ThermoLabsystems, Dreieich). The measurements were carried out at 25˚C in a 
TECAN spectrofluorimeter (Ascent, Lab Systems, Frankfurt) using an excitation 
wavelength of 390 nm, an emission wavelength of 475 nm and spectral bandwidths 
of 2.5 and 2.5 nm for emission and excitation respectively. 
3.2.5.3 Circular Dichroism 
 
The circular dichroism spectroscopy method measures the differences between the 
absorption of left handed circularly polarized and right handed polarized light. A 
typical CD curve contains both negative and positive values depending on the 
wavelength. The far UV spectral range (190- 250 nm) is used to study the secondary 
structure of the protein. Structures such as α-helix, ß-sheet, and random coiled give 
rise to characteristic shapes and amplitudes of the CD spectrum (Figure 3.1). All CD 
measurements were carried out with a Jasco J-810 CD spectrometer (Jasco, Gross-
Umstadt, Germany) in a cuvette with a path length of 0.1 cm. The parameters were: 
 
Figure 3.1 CD spectra of reference structure. 
Representative CD spectra of proteins are shown. A protein with α-helix structure has a two spectral 
peak minima at 208 and 222nm.A protein with ß-sheet structure has a single spectral minimum at 
215nm and a random coiled protein has a spectral minimum at 198nm. Picture reproduced from  
http://www.fbs.leeds.ac.uk/facilities/cd/images/1.png 
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scanning speed – 100 nm/min; bandwidth - 0.1 nm; response time - 4 s; 
measurement temperature, 20°C. 
3.2.5.4 Light Scattering (90°) 
The basic principle of light scattering is that the size of a molecule (with certain 
approximations) is directly proportional to the amount of scattered light. Hence this 
method is used to monitor the aggregation of TauRDΔ. Measurements were performed 
with a Spex Fluromax spectrophotometer (Polytec, Waldbronn, Germany), using 3x3 
mm quartz microcuvettes (Hellma, Muhlheim, Germany) with 20µl of sample volume 
at concentration of 50µM. Experimental parameters were excitation and emission 
wavelength at 350 nm (90° scattering); scan range 320-400 nm: excitation slit width - 
5 nm; emission slit width - 5 nm; integration time - 1 s; photomultiplier - 950 V. Each 
time two spectra were scanned and averaged. The scattering of the buffer was 
always subtracted.  
3.2.5.5 Dynamic (quasielastic) Light Scattering 
The principle of dynamic light scattering (or quasielastic light scattering) is based on 
fluctuations of the scattering particles caused by Brownian motion, which in turn 
depends on particle size and shape. The method allows one to analyze contributions 
from different types of particles (e.g. monomers and oligomers) provided that the size 
differences are sufficiently large (about 5-fold or more). Measurements of FPLC 
fractions were performed with a Zetasizer Nano ZS (Malvern, Herrenberg, Germany) 
containing a 5-milliwatt Helium-neon 633-nm laser at 173° measurement angle. The 
system was calibrated with latex beads of 30 and 150nm. The samples were diluted 
to 10µM in water. 20µl of sample in a low-volume quartz batch cuvette (ZEN2112) 
was used and the samples were thermally equilibrated at 25 °C for 2 min. Particle 
size was obtained as an average of three measurements with 20 runs each and 
expressed as intensity or volume distribution.  
3.2.6 Imaging methods: 
3.2.6.1 Transmission electron microscopy 
Electron microscopy is an imaging technique in which a beam of electrons passes 
through a specimen and scattered electrons form a magnified high resolution image 
on a photographic film or on a CCD camera. To enhance the structural details of a 
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sample, staining with heavy metals such as osmium, lead or uranium can be used 
because the heavy atoms, having dense nuclei, scatter the electrons out of the 
optical path and hence areas where electrons are scattered appear dark on the 
screen or on a positive image. 
The protein samples were diluted to 16.6 µM and placed on 200 mesh carbon coated 
copper grids which were glow discharged to generate a hydrophilic surface. The 
samples were incubated on grids for 3 min, washed thrice with H2O and negatively 
stained with 2 % filtered uranyl acetate for 45-90 seconds (depending on the sample) 
followed by a final wash with H2O. The specimens were examined with a JEOL 
electron microscope at 200 kV at the Electron Imaging facility of CAESAR. Images of 
aggregated samples were captured with a CCD camera using EMMENU 4 software. 
3.2.6.2 Atomic force microscopy 
Atomic force microscopy (AFM) is a technique to obtain images at a high 
(nanometer) resolution by scanning the sample surface with a very sharp (end radius 
ca. 10 nm) probe (cantilever) and recording the deflection of a cantilever. When the 
probe is brought close to the sample surface, forces between the probe and sample 
leads to the deflection which is received in the photodiode and is proportional to the 
height of the particle. 
AFM sample preparation: Magnetic steel disks 12mm diameter were used as a base. 
10-15 mm diameter disc shaped Teflon sheets were glued using Loctite 406 on 
magnetic steel disks. 10mm diameter disc shaped mica sheets (AFM grade - 
thickness 0.5mm) were glued on the Teflon sheets using the two component epoxy 
glue Araldite-Rapid after cleaving the bottom layer of the mica sheets and allowing it 
to dry overnight at room temperature. The fluid cell was washed thoroughly and 
attached to the AFM head before the sample preparation. 1-2µM of protein sample in 
adsorption buffer (oligomer, monomer, and/or fibril) was placed on the freshly 
cleaved mica sheets and allowed to adhere to the surface for 10-20 min at room 
temperature. The non-adherent proteins were removed by washing with imaging 
buffer carefully 4-5 times by pipetting. 
AFM Imaging: AFM imaging was done in oscillation mode for all Tau samples. The 
cantilever was inserted in the cantilever holder attached with fluid cell. This 
assembled setup was attached to the AFM head. The laser was aligned on the end 
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of the tip and the set up was thermally equilibrated for 10-20 min at room 
temperature. The initial approach of the cantilever to the surface was performed in 
the constant force mode with the relative set point of 1V and the scan size was at 
0nm. The cantilever was retracted to 50µm from the surface. The oscillation of 
frequency and drive amplitude for oscillation mode imaging was chosen using the in-
built auto-tuning procedure (using an SNL 10 cantilever). Frequency sweep was 
performed to find the first resonance peak of the cantilever. In air the first resonance 
peak appeared around 60 kHz. The sweeping was done on the liquid and the first 
resonance peak in the liquid was between 5-6 kHz. A 5% offset of oscillation 
amplitude was applied to the operating frequency of the cantilever and the target 
amplitude was set at 1V. The parameters such as x, y offset were kept at 0 nm and 
the z offset was kept at maximum. The surface was approached in oscillation mode 
with an amplitude set point of 50-60% of the target amplitude. Once the surface was 
reached, the minimal contact between the sample and cantilever was maintained by 
altering the amplitude set point manually. The images were acquired at a scan rate of 
1Hz with the resolution of 512 by 512 pixels. The scan size for the overview images 
were scanned for either 10µm or 5µm. For oligomers, 1µm scan size images were 
acquired. During the scanning the gains and amplitude set points were altered 
manually often to keep a minimal force between the cantilever and the sample. The 
images were acquired using the Nanoscope III microscope facility at CAESAR. The 
acquired images were processed by the Nanoscope III software. 
3.2.7 Cell culture 
3.2.7.1 SH-SY5Y cells maintenance 
The SH-SY5Y cells were grown in DMEM medium supplemented with 15% FCS and 
1X penicillin and streptomycin antibiotics (Complete medium). The cells were 
generally cultured up to 70-80% confluence at 37°C with 5% CO2 in a CO2 incubator.  
The cells were subcultured by the trypsin digestion method as follows. Cells were 
washed with tissue culture grade PBS. 1ml of trypsin EDTA solution was added to 
the SH-SY5Y cells (T25 flasks) and incubated at 37°C in the CO2 incubator for 2-3 
min. 4ml of the complete medium was added to the cells to prevent the excessive 
digestion by trypsin. The cells were centrifuged at 1250rpm for 1-2 min to pellet down 
the cells and sub cultured (1:5 – 1:10 ratio) in 5ml of complete medium.  
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3.2.7.2 Freezing of SH-SY5Y cells 
The freezing media (50% FCS+30% DMEM+20% DMSO) was prepared and filter 
sterilized using syringe filters. The cells grown in T-75 flasks were trypsinized for 2-3 
min. 4ml of the complete medium was added to the cells to prevent the excessive 
digestion. The cells were centrifuged at 1250rpm for 5 min at RT. The medium was 
removed and the cells were resuspended in 2-3 ml of freezing medium. The number 
of cells was counted in a Neubauer chamber. 1x106 cells/cryo vial was prepared and 
stored in an isopropanol container for 24 h at -80°C and then transferred to the liquid 
nitrogen tank for longer storage. 
3.2.7.3 Preparation of primary neuronal cells 
Before the preparation, all surgical instruments were sterilized in 70% ethanol 
followed by heat sterilization. A pregnant rat at E18 days was anesthetized using 3-4 
ml of dichloromethane and sacrificed by cervical dislocation method. The uterus with 
the embryo was removed by making an incision on the stomach. Embryos were 
collected by removing the embryonic sac. The heads were removed and placed it on 
ice cold HBSS. By holding the eyes of the embryo using a forceps, an insertion was 
made in the middle of the brain (forebrain - midbrain junction). Using a sharp forceps 
the skull was removed without damaging the brain. The tissues covering the 
hippocampus were removed by micro scissors. The meninges (a layer which covers 
the brain) were removed out and then the cortex and hippocampus were dissected 
out. The tissues were minced into small pieces and collected in 15ml conical tube to 
settle down. The supernatant was discarded and 5ml of trypsin was added to the 
cortex tissue (1-2ml of trypsin for hippocampal tissue). The tissues were incubated in 
a water bath at 37°C for 8 min and then twice the volume of plating medium was 
added. The tissues were allowed to settle down and the supernatant was removed. 
For a pair of hippocampi, 0.5ml of HBSS was added and the cells were dissociated 
by pipetting. For cortical cells, 50 ml of HBSS were directly added after dissociation in 
2-3 ml of HBSS buffer. 10µl of dissociated cells were mixed with 10µl of 0.4% trypan 
blue for 5 min at room temperature and then the cell number was counted using a 
Neubauer chamber. Rat primary cortical and hippocampal neurons were plated on 96 
well plate (15,000 cells/well) or 6 well plate (250,000 cells/well). After 3 h the cells 
were changed to Neurobasal medium.  After 3 days AraC was added to the medium 
to arrest the growth of the glial cells. Then the cells were grown for 21-28 days. 
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3.2.7.4 Protein transfection 
SH-SY5Y cells were plated at a density of 150,000 cells/well in 6 well plates and left 
overnight at 37°C. Xfect protein transfection reagent kit (Clontech) was used to 
transfect the protein of our interest into the neurons. 15µl of Xfect transfection 
reaction mixture was mixed with 85µl of deionized water in a tube. In another tube 
the protein of interest and the Xfect transfection buffer was made up to the final 
volume of 100µl. Both the reaction mixture were added together and mixed well by 
pipetting them up and down slowly for 10-15 times and then incubating them at RT 
for 30 min. 400µl of serum free medium was added to this mixture and mixed well 2-3 
times by pipetting. In case of rat primary neurons, the conditional medium was used. 
The whole content (600µl) was added on the cells and incubated for another 2 h. 
After that 2ml of medium with the serum was added on the cells and incubated for  
15 h. 
3.2.7.5 Cell toxicity assays 
SH-SY5Y cells (15,000 cells/well) were plated on a 96 well plate and left it overnight 
in a CO2 incubator. The cells were incubated with protein of interest for specific time 
periods and then used for toxicity assays. In all toxicity assays, the measurements 
were normalized to buffer control to evaluate the difference. Rat primary cortical and 
hippocampal neurons (15,000 cells/well in a 96 well plate and grown for 3 weeks) 
were treated similarly.   
MTT assay 
The assay is based on the cleavage of the tetrazolium salt MTT (3-(4,5-
Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium bromide) in the presence of an 
electron-coupling reagent. The water-insoluble formazan salt produced must be 
solubilized in an additional step. Tetrazolium salts are cleaved to formazan by the 
succinate-tetrazolium reductase system which belongs to the respiratory chain of the 
mitochondria, and is only active in metabolically intact cells. This bio-reduction occurs 
in viable cells only, and is related to NAD(P)H production through glycolysis. 
Therefore, the amount of formazan dye formed directly correlates to the number of 
metabolically active cells (Vistica et al., 1991). 
  Materials and Methods 
33 
 
SH-SY5Y cells and rat primary neurons were treated with oligomers for certain time 
periods. After the incubation time, 10µl of MTT solution I (3-(4,5-Dimethylthiazol-2-yl)-
2,5-Diphenyltetrazolium bromide) was added to the cells and incubated for 4 h at 
37°C in a CO2 incubator. After 4 h, 100µl solubilization solution (10% SDS in 0.01 M 
HCl) was added to the cells and incubated further overnight at 37°C in a CO2 
incubator. After the incubation time, the absorbance was recorded at 550 nm and the 
reference wavelength was 690 nm.  
XTT assay  
This assay is based on the cleavage of yellow tetrazolium salts XTT (2,3-Bis-(2-
Methoxy-4-Nitro-5-Sulfophenyl)-2H-Tetrazolium-5-carboxanilide) to form an orange 
formazan dye by metabolically active cells. This conversion takes places only in the 
viable cells. This formazan dye formed is soluble in aqueous solutions and is directly 
quantifiable (Gerlier and Thomasset, 1986). 
XTT solution: 2ml of XTT labelling reagent was mixed with 40µl of electron coupling 
reagent and mixed very well. SH-SY5Y cells and rat primary neurons were treated 
with oligomers for certain time periods. After incubation, 50µl of XTT solution was 
added to the cells and incubated overnight at 37°C in a CO2 incubator and then the 
absorbance was recorded at 450 nm with the reference wavelength of 690 nm.  
Alamar blue assay 
Alamar blue is a cell viability indicator that uses the natural reducing power of living 
cells to convert resazurin to the fluorescent molecule, resorufin. The active ingredient 
of alamarblue (resazurin) is a nontoxic, cell permeable compound that is blue in color 
and virtually nonfluorescent.  Upon entering cells, resazurin is reduced to resorufin, 
which produces very bright red fluorescence. Viable cells continuously convert 
resazurin to resorufin, thereby generating a quantitative measure of viability and 
cytotoxicity (Page et al., 1993). 
SH-SY5Y cells and rat primary neurons were treated with oligomers for certain time 
periods. After the incubation, 10µl of alamar blue solution was added to the well 
containing 100µl of medium and cells and incubated for 4 h at 37°C in a CO2 
incubator. The fluorescence intensity of resorufin was measured in a 
spectrophotometer using 560 nm excitation and 590 nm emission filter settings. 
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LDH release assay 
Lactate dehydrogenase (LDH) is a soluble cytosolic enzyme that is released into the 
culture medium following loss of membrane integrity resulting from either apoptosis 
or necrosis and hence LDH activity can be used as an indicator of cell membrane 
integrity. The LDH kit (Roche) measures LDH activity in the culture medium using a 
coupled two-step reaction. In the first step, LDH catalyzes the reduction of NAD+ to 
NADH and H+ by oxidation of lactate to pyruvate. In the second step, diaphorase 
uses the newly-formed NADH and H+ to catalyze the reduction of a tetrazolium salt 
(INT) to highly-colored formazan which absorbs strongly at 490 nm (Decker and 
Lohmann-Matthes, 1988). 
45µl of dye solution was added to 1µl of catalyst solution and mixed well (ratio 45:1). 
Then 50µl medium from the wells were collected and 50µl of LDH reaction mixture 
was added to the medium and incubated at RT in the dark for 30 min. The reaction 
was stopped by the addition of 10µl of 1N HCl and incubated for another 1 h at 4°C. 
The absorbance was measured at 490 nm. 
3.2.7.6 Functional assays 
Calcium imaging: Intracellular calcium levels were measured using the Fura-2 
ratiometric dye. Upon entering the cells Fura 2-AM is cleaved by cellular esterases. 
Fura-2 is free to interact with the calcium in the cells. Fura-2 is excited at two 
wavelengths (380 nm – free form; 340 nm – calcium bound form) and emits the light 
at 516 nm.  Therefore the changes in the ratio of 340nm and 380 nm are calculated 
to measure the intracellular calcium level. The primary rat hippocampal neurons were 
grown on 96 well plates with the density of 15000 neurons per well. The conditional 
medium were collected and stored. The cells were incubated with 4µM Fura-2 and 
2% F127 for 30 min at 37°C. After the incubation, the Fura 2 dye was removed and 
the cells were washed with 1X HBSS.  The cells were filled with 80µl of calcium 
imaging solution and imaged on a fluorescence microscope (Cell Observer, Zeiss) at 
20X magnification.Multiple acquisition mode was used to image in different wells 
simultaneously. The fileds were chosen and imaged for first 10 min. Then the 
required concentration of the sample (Buffer, TauRDΔ monomer and oligomers at 
different concentrations) was added to the calcium imaging buffer and the image 
acquisition was started immediately for another 30 min.  
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ROS Imaging: Reactive oxygen species levels were measured using the DCFDA 
dye. Carboxy-DCFDA can passively diffuse into cells and is colorless and 
nonfluorescent until the acetate groups are cleaved by intracellular esterases to yield 
the fluorescent fluorophore, 5-(and-6)-carboxy-2',7' –dichlorofluorescein (DCF). Upon 
the production of super oxide and peroxy radicals, this DCF is oxidized and shows an 
increase in the fluorescence intensity.  4µM of DCFDA dye was incubated along with 
2% F127 (facilitates the solubilization of water insoluble dyes) for 30 min on rat 
primary hippocampal neurons. After the incubation, the fura 2 dye was removed and 
the cells were washed with 1X HBSS.  The cells were filled with 80µl of calcium 
imaging solution and imaged by fluorescence microscopy as described above.  
Confocal microscopy 
Analysis of neurons, tissue cultures and slices was done by imaging on an LSM 700 
confocal microscope using a 63X objective. Dendritic spines were counted at 30µm 
distance from the cell soma for the length of another 50µm. From each coverslip, a 
minimum of 10 neurons were imaged and counted for spine density analysis. 
Flow cytometry (FACS) 
Flow cytometry is a laser-based, biophysical technique in cell counting, by 
suspending cells in a stream of fluid and passing them through an electronic 
detection apparatus. Blue laser (488 nm laser) was used to excite ThS (Ex:440 nm/ 
Em:521 nm) and red laser (638 nm laser) was used to excite APC (Ex:633 nm/ 
Em:665 nm). The instrument was used according to the manufacturer's 
specifications. 
Annexin V staining 
Apoptosis is called programmed cell death where the loss of plasma membrane is 
one of the earliest features. In apoptotic cells, the membrane phospholipid 
phosphatidylserine (PS) is translocated from the inner to the outer leaflet of the 
plasma membrane. Annexin V is a 35-36 kDa Ca2+ dependent phospholipid-binding 
protein that has a high affinity for PS, and binds to cells with exposed PS. APC 
(Allophycocyanin) Annexin V staining can identify apoptosis at an earlier stage than 
assays based on nuclear changes such as DNA fragmentation.  
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SH-SY5Y cells were treated with the protein of interest for 15 h. The cells were 
trypsinized for 3 min at 37°C in a CO2 incubator, collected in a tube and centrifuged 
at 1250 rpm for 5 min at RT. The supernatant was removed and the cells were 
suspended in 100µl of 1X annexin binding buffer. 5µl of annexin V dye was added to 
the cells and incubated in the dark for 30 min at RT. The cells were washed with 1X 
annexin binding buffer and collected in 1X annexin binding buffer in a flow cytometry 
tube. Cell counting was performed in Gallios Beckman-Coulter Flow cytometer. 
20,000 cells were counted per sample without any gating. The excitation and 
emission of Annexin V APC dye used was 650nm and 660 nm respectively.  
ThS staining 
Thioflavin S binds to the ß-sheet structure of aggregates. SH-SY5Y cells were 
treated with the protein of our interest for 15 h. One hour before harvesting the cells, 
0.0005% ThS was added to the cell culture medium and allowed them to enter the 
cells. The medium was collected and the cells were trypsinized for 3 min at 37°C and 
then cells were collected in a tube along with the pre collected medium. The cells 
were centrifuged at 1250 rpm for 5 min at room temperature. Then the supernatant 
was removed and the cells were resuspended in PBS buffer. The ThS positive cells 
were counted on flow cytometer without any gating. 20,000 cells were counted for 
each condition. 
3.2.7.7 Immunocytochemistry 
Rat primary neurons were treated with the protein of interest for different time 
intervals. After the incubation time, the cells were fixed with 4% sucrose and 3.7% 
formaldehyde in PBS solution for 30 min at 37°C, then washed with 1X PBS, 3 times. 
The cells were permeabilized and blocked using 5% BSA, 0.5% Triton X 100 in PBS 
for 6 min at RT and then washed thoroughly three times with 1X PBS. The primary 
antibody was diluted in 5% BSA and incubated on cells overnight at 4°C. Unbound 
antibodies were washed with 1X PBS three times. The secondary antibodies and 
dyes were incubated for 1 h at 37°C. The excess antibodies were washed three 
times with 1X PBS. 10µg/ml DAPI was incubated for 10 min at room temperature and 
washed once with 1X PBS. Finally the cells were mounted using poly mount solution 
and the coverslips were dried at 4°C overnight.  
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3.2.8 Tissue culture 
Organotypic Hippocampal Slice Culture 
Organotypic hippocampal slice cultures (OHSC) were prepared as described 
(Stoppini et al., 1991) with modifications. All the dissection materials were sterilized 
before the preparation. 8 days old wild type mice were sacrificed and the brain was 
quickly removed. The hippocampi were dissected out without destroying the 
architecture of hippocampus. The hippocampi were transferred to the filter paper and 
placed on the tissue chopper to prepare 400µm thick transverse slices. The slices 
were transferred to the medium quickly and the intact hippocampus slices were 
transferred to the semi-porous (0.4 µm) cell culture inserts. The inserts were 
equilibrated in the medium 1 h before the preparation and stored at 37°C in a CO2 
incubator. 8-10 slices were placed on one insert in a six well plate containing 1 ml 
slice culture media. Every third day the medium was replaced with the fresh media. 
The slices were maintained for 11 days in vitro. After 11 days, the slices were treated 
with respective protein of our interest for another 24 and 48 h.  
3.2.8.1 Immunohistochemistry 
After the treatment, the slice culture media was completely removed and the slices 
were fixed with 4% formaldehyde overnight at 4°C. The inserts were washed with 1X 
PBS 3 times, 10 min each at the room temperature on a shaker. The inserts were 
split into 3 pieces with 3-4 slices/ inserts and incubated with 0.1 M glycine for 20 min 
at room temperature. The slices were permeabilized with 0.5% triton X 100 in PBS 
overnight at 4°C, then washed 3 times with 1X PBS for 15 min each, at room 
temperature. Then the slices were blocked with 20% horse serum for at least 4 h at 
room temperature. The slices were incubated with primary antibody diluted in 5% 
horse serum and 0.05% triton-100 in PBS for at least 48 h and then the slices were 
washed with 1X PBS, 3 times with 10 min interval. Then the secondary antibody was 
also diluted in 5% horse serum and 0.05% triton X-100 and incubated for at least 24 
h. The slices were washed with 1X PBS, 3 times, at 10 min interval and then the 
slices were mounted using poly mount solution. 
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3.2.9 Animal models 
3.2.9.1 Brain homogenate preparation 
Animals were sacrificed and the brains were removed and frozen in liquid nitrogen. 
Before the homogenate preparation, the brain sample was thawed by keeping it on 
ice. 800µl of 1x lysis buffer was added and the tissue was minced using a 1ml 
syringe attached with 18G needle and later with 24 G needle. The sample was 
placed on ice for 30 min. The sample was resuspended with a pipette and was 
centrifuged at 14,000 rpm at room temperature. The supernatant containing the 
proteins was collected and the protein concentration was estimated using BCA 
method. 
3.2.9.2 Sarcosyl extraction of insoluble Tau 
Three times more volume of buffer H was added to the brain tissue (w/v) (For ex:  
57mg of cortex tissue was homogenized in 171 µl of buffer H). The sample should be 
kept on ice throughout the experiment. The sample was homogenized for 30 seconds 
and kept on ice for 1 minute. The same step was repeated once more. Later the 
sample was incubated on ice for 15 min and then centrifuged at 1000 rpm for 3 min 
at 4°C. The tissue was resuspended using pipettes and transferred to Beckman 
centrifugation tube and centrifuged for 26,000 rpm (TLA 100.3) for 20 min at 4°C. 
The supernatant (S1) was collected into another tube. To the pellet, buffer H was 
added again and the same step was repeated. The supernatant (S2) was collected 
and added to the same tube where supernatant (S1) was stored. The volume of 
supernatant S1 and S2 was measured and then 10% of N-lauroyl-sarcosinate and 
10µg/ml ß-mercaptoethanol was added in a 9:1 ratio to the supernatant I and II 
mixture. This mixture was incubated at 37°C for 1.5 h – 2 h in a shaking condition 
and then centrifuged at 61,000 rpm (TLA, 100.3 rotor) for 35 min at 20°C. The pellet 
was very small but clearly visible. The supernatant was carefully collected (S3) and 
the pellet was rinsed in 100µl of 1X TBS and then the TBS was removed carefully 
without disturbing the pellet.  The pellet was resuspended in 0.5µl of 1X TBS for each 
mg of brain tissue. The samples were run on SDS gel for further analysis. 
3.2.9.3 Iodixanol gradient centrifugation 
60% Optiprep Iodixanol was diluted in water and placed in a Sorvall centrifugation 
tube from top to bottom in an increasing concentration (5, 10, 20,25,30,40 and 50%). 
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On top of the 5% layer, 100µl of the brain homogenate was placed and centrifuged at 
65,000 rpm (TV 865 rotor) at 4°C for 3 h. At the top of the centrifugation tube, a hole 
was made using a needle to let the air come in and from the bottom of a tube the 
fractions were collected by puncturing the tube at the bottom. 500µl fractions were 
collected and were run on an SDS gel and blotted with K9JA antibody for the 
detection of Tau protein. 
3.2.10 Statistics 
All experimental data were normalized with buffer controls. The statistics was done 
using graph pad prism software. The significance of differences was analyzed by 
one- way and two-way ANOVA test with Tukey´s post hoc test. In all the experiments 
the confidence interval was set at 95%. Hence a p value < 0.05 was considered to be 
statistically significant. 




As described in the Introduction section, it is known that the TauRDΔ mouse model 
shows pronounced neurodegeneration (Mocanu et al., 2008). However, switching off 
the expression of the soluble TauRDΔ reduces Tau pathology and improves memory 
(Sydow et al., 2011, Van der Jeugd et al., 2012). Recent reports have suggested that 
small oligomeric species are responsible for the toxicity of Tau (Lasagna-Reeves et 
al., 2010, Kumar et al., 2014, Flach et al., 2012). This provided the motivation for 
investigating the nature of TauRDΔ oligomers and their toxicity. 
4.1 Oligomers interact via cys-cys bonding in ΔK280 transgenic mice  
In order to characterize the oligomers of mutant repeat domain or full length Tau 
(TauRDΔ and TauFLΔ) generated in the transgenic mouse models, mice aged > 18 
months were sacrificed and the insoluble and soluble Tau protein was fractionated 
using the sarcosyl extraction procedure. The insoluble Tau was extracted in fractions 
P3 and contains both wild type mouse tau (Mr~55kDa in the SDS gel) and human 
TauRDΔ (Mr~14 kDa) (Figure 4.1 A). The soluble (S3) fractions were also run on a 
SDS gel and showed some oligomeric bands in the range of 80kDa (in case of 
TauRDΔ mouse brain homogenates (red arrow Figure 4.1 A) and ~ 100, 120 and 200 
kDa (red arrows Figure 4.1 B) in the case of TauFLΔ mouse brain which indicate that 
the oligomeric species are present. These oligomeric bands did not appear in P3 
fraction which suggests that these bands represent small soluble oligomeric species. 
We consider 2-10 molecules of Tau as low-n oligomers whereas the protein retained 
in the gel pockets are considered as high-n oligomers and/or pre-fibrillar or fibrillar 
aggregates.  Since Tau-Tau interactions are promoted by disulfide crosslinks, a 
portion of the S3 samples were mixed with sample buffer without ßME (which breaks 
the disulfide bridges) and run on a gel. Interestingly, a smear of bands appeared on 
the western blot from 60 kDa to >200 kDa in case of S3 fraction of TauRDΔ. Similar 
observations were made in case of TauFLΔ mouse brain homogenate. This suggests 
that there are higher order oligomeric species in both TauRDΔ and TauFLΔ mouse 
models connected via cys-cys bonding. However, it is not clear whether the smears 
contain only the exogenous human Tau and/or also endogenous mouse Tau.  




Figure 4.1 Tau oligomers in brains of transgenic mice. 
Insoluble Tau and soluble Tau were separated from brain homogenates of cortex tissue from pro-
aggregant full length (B) and repeat domain (A) transgenic mouse brains using the sarcosyl 
extraction method. P3 fractions contain the insoluble Tau and S3 fractions contain soluble Tau. The 




respectively and blotted with 
K9JA antibody (1:20,000 dilution). The blots display the smear of Tau proteins in the S3 fractions, in 
the absence of ßME suggesting the interaction of Tau-Tau via disulfide bridges (Fig A –Lanes 6,7;  
Fig B – Lanes 10,11,12). The red arrows on fig A and B show the SDS and DTT stable tau oligomers. 
The number on the bottom denotes the animal numbers. ßME – ß mercaptoethanol; hT40- purified 
recombinant full length tau protein; The dotted line separates the stacking gel from resolving gel. 
4.2 Separation of Tau oligomers by iodixanol gradient centrifugation 
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To study the properties of the Tau oligomers, we applied iodixanol gradient 
centrifugation to separate the tau oligomers from the pool of other proteins. This 
method separates the molecules on the basis of their density. We used supernatant 3 
from the sarcosyl extract, as it contains only the soluble protein with Tau monomers 
and oligomers. With this method it is possible to separate different forms of Tau 
protein in different gradient fractions. Figure 4.2 shows exogenous human Tau 
(TauRDΔ) in 5-25% of iodixanol gradient fractions. Interestingly, at 40% iodixanol 
gradient, a faint band of SDS stable Tau oligomers at ~80 kDa is visible (red arrow). 
A similar observation was also made for S3 fractions of TauFLΔ mouse brain. The full 
length Tau protein (~65 kDa) was found in the fractions of 25 -35% iodixanol 
gradient. As shown in Figure 4.1B, there is also a faint additional band at ~100 kDa in 
the 35% iodixanol fraction (Figure 4.2 B; red arrow). 
In both animal models, mouse Tau could not be separated from human Tau even 
though the molecular weights are different (mouse Tau - 55 kDa and human Tau 
(TauRDΔ - 14kDa; TauFLΔ– 65kDa). One possibility is a strong interaction 
(coaggregation) between human and mouse Tau or that the oligomeric species 
contain a mixture of both endogenous mouse Tau and exogenous human Tau and 
become separated when treated with the sample buffer and SDS. This result 
suggests that separation of only the oligomeric form of exogenous human Tau from 
monomeric Tau and mouse Tau is not possible by iodixanol gradient.   
 
 




Figure 4.2 Separation of Tau oligomers by iodixanol gradient centrifugation. 
100µl of S3 fraction from Tau
RDΔ
 (A) and Tau
FLΔ 
(B) mouse brain homogenates were applied on the 
bed of the iodixanol gradient and centrifuged at 65,000 rpm (TV 865 rotor) for 3 h. Western blot 
analysis (K9JA antibody, 1:20,000 dilution) of the fraction of iodixanol gradient shows that the proteins 
were separated. Oligomers are seen on the gel as faint bands at higher density (red arrow). In (B), 
recombinant hTau40 protein was loaded as marker along with the mouse sample to differentiate the 
electrophoretic movement of mouse Tau from the human Tau. Note: Tau
RDΔ
 protein was fractionated 
at 5-25% of the gradient whereas Tau
FLΔ 
protein was fractionated at 25-35% suggesting the ability of 
the method to separate the protein based on density. S3 = Supernatant 3 sample used for iodixanol 
centrifugation. 
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4.3 Preparation of TauRDΔ protein in vitro 
 
Figure 4.3 Preparation of  Tau
RDΔ
 protein in vitro 
A) Representative chromatogram of Tau
RDΔ
 protein prepared from 4 liters of bacterial culture and 
purified by Sepharose SP HP 16/10 cation exchange chromatography column. Note: The protein elutes 
early in the gradient (black arrow). The red curve represents absorbance of protein at 214nm. The 
green curve represents the concentration of Mono S B (high ionic strength) buffer. B) The protein (260-
310 ml) was eluted as fractions in tubes (14-28) and was run on a 17% SDS gel and stained by 
Coomassie Blue.  
The protein TauRDΔ was prepared in large quantity (~120 mg) and purified by 
Sepharose SP 16/10 cation exchange chromatography column as Tau protein is 
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positively charged. It binds to the negative ligand in the column and elutes later in the 
chromatogram whereas unbound protein is collected in the flow-through. A 
representative chromatogram is shown in Figure 4.3 A. The protein was eluted early 
in the elution gradient (black arrow) as the ionic strength (green curve) is increased in 
the buffer in a gradient fashion (Mono S A and Mono S B buffer). The purity of these 
fractions was analyzed by SDS gel and Coomassie Blue staining (Figure 4.3 B). The 
fractions show homogenous soluble monomeric protein without higher aggregates. 
This protein was used for further analysis. 
4.4 Aggregation kinetics of TauRDΔ 
Under pathological conditions, Tau protein is aggregated to filaments and oligomeric 
precursors. As a model of Tau aggregation, we used TauRDΔ protein (von Bergen et 
al., 2000).  The repeat domain of Tau aggregates more readily than full-length Tau 
into bona fide "paired helical filaments", and the "pro-aggregant" mutation (deletion of 
lysine at position 280) increases the propensity for ß-sheet structure even further 
(Barghorn et al., 2000). We therefore investigated the rate of aggregation of TauRDΔ 
protein in vitro under different buffer conditions by several methods in order to find 
the best conditions for oligomer preparation. The aggregation was carried out in the 
absence of heparin (an aggregation inducer), as TauRDΔ aggregates itself because of 
its strong ß-propensity. 
4.4.1 Aggregation monitored by light scattering and fluorescence assays 
50µM of TauRDΔ protein was diluted in PBS pH 7.4 and TBS pH 9.0. Prior to 
aggregation, the samples were heated with 1mM DTT for 20 min at 95°C in the 
presence of DTT to remove unwanted disulfide bridges (Schweers et al., 1995) and 
thus to monomerize the protein. After that the protein samples were incubated at 
37°C for different time intervals.  
 The aggregation was monitored by assays of static UV light scattering at 350nm 
(which records particle size), Thioflavin S fluorescence (sensitive to amyloid like 
cross-ß-structure) and ANS fluorescence (reports on protein conformation). Under 
both buffer conditions (PBS pH 7.4 and TBS pH 9.0), TauRDΔ aggregates in a similar 
fashion with similar assembly rates and final levels (Figure 4.4 A). A similar 
observation was made for the case of static light scattering experiments, i.e. roughly 
comparable rates of assembly and final levels (Figure 4.4 B).  




Figure 4.4 Aggregation of Tau
RDΔ
 by LS and fluoresence assays 
Time course of aggregation of Tau
RDΔ
 protein was monitored by static UV light scattering, Thioflavin S 
and ANS fluorescence. A) ThS fluorescence intensity reached the maximum only after 8 h under both 
buffer conditions PBS pH 7.4 (blue lines) and TBS pH 9.0 (red lines). There is no significant change in 
the ThS fluorescence. B) Tau
RDΔ
 protein in TBS pH 9.0 was aggregated at the same rate as PBS pH 
7.4. Hence no significant difference is observed. C) ANS fluorescence intensity reached the maximum 
only after 8 h under both buffer conditions PBS pH 7.4 (blue lines) and TBS pH 9.0 (red lines). There 
is no significant change in the ANS fluoresence. 
 
ANS is a sensitive reporter of protein conformation. ANS binds to hydrophobic 
residues of a protein through its aromatic ring and positively charged amino acids 
through its sulfonate group. ANS fluorescence is increased during unfolding of a 
protein where the hydrophobic residues are available for binding. During aggregation, 
we observed an increase in the fluorescence intensity of ANS which reaches 
saturation after 8 hours in both buffer conditions (Figure 4.4 C) without a significant 
difference. This was contrary to expectations, since during aggregation Tau changes 
from a disordered state to an ordered ß-structured state. These assays suggest that 
conformational changes in the TauRDΔ take place under both buffer conditions. 




Figure 4.5 Sedimentation analysis of Tau
RDΔ 
aggregates. 
The aggregates formed under both the buffer conditions (PBS pH 7.4 (A) and TBS pH 9.0 (C)) were 
sedimented by centrifugation (61,000 rpm; TLA 100.3 rotor). The supernatant and the pellet fractions 
were run on a 17% SDS gel and stained with Coomassie blue. Note: There is a time dependent 
increase in the protein amount in the pellet fraction in both buffer conditions, but the TBS buffer 
condition generates 10% less aggregates. (B and D) The intensity of Tau
RDΔ
 monomeric band was 
quantified by Image J software and plotted as a graph. S = Supernatant; P=Pellet; M=Marker and h= 
hours. 
 
We also performed sedimentation analysis of these aggregated samples under both 
buffer conditions. At 0 hours, under both buffer conditions, we observed aggregates 
in the pellet fraction which is typical of this protein. Later during aggregation,   TauRDΔ 
in TBS pH 9.0 and PBS pH 7.4 (Figure 4.5) showed significant increase in the protein 
aggregates in the pellet fraction. It appears that TBS, pH 9.0 condition has 10% less 
aggregates in the pellet fraction at 24 h compared to PBS,pH 7.4. This suggest that 
TauRDΔ protein in TBS pH 9.0 condition contains less aggregates and possibly favors 
oligomers. 
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4.4.2 EM and AFM reveal twisted fibrils and oligomeric structures 
 
Figure 4.6 Analysis of  Tau
RDΔ
 aggregates by EM and AFM  
Electron micrographs of Tau
RDΔ 
at different time points of aggregation and in different buffer 
conditions. A and B show the aggregation of Tau
RDΔ 
in PBS pH 7.4. (A) At 30 min, Tau
RDΔ
 protein 
forms globular shaped aggregates (black arrow) and prefibrillar aggregates. (B) After 72 h of 
aggregation, Tau
RDΔ 
protein shows clear long twisted fibrils. C and D show the aggregation of Tau
RDΔ 
in TBS pH 9.0. At 30 min of aggregation, only few oligomers are present (C). Even after 120 h, small 
oligomeric species were found along with bowtie shaped short fibrils. E and F show AFM images of 
the Tau
RDΔ 
aggregation at 72 h at pH 7.4 and pH 9.0 respectively.  
 
The morphology of the aggregates formed by TauRDΔ under different buffer conditions 
was studied by EM and AFM. After 72 h (in PBS pH 7.4), there were long twisted 
fibrils typical of Alzheimer PHFs (Figure 4.6 B; black arrow and E; white arrow), but 
also a heterogeneous mixture of shorter fibrils and oligomeric aggregates. These 
intermediate prefibrillar aggregates were already observed 30 min after starting 
assembly (Figure 4.6 A arrow). 
In contrast to PBS pH 7.4, we observed that at pH 9.0 the fibrils tend to be much 
shorter and have a bow-tie like shape (Figure 4.6 D), yet have a similar ThS signal. 
At 30 min of aggregation only few small oligomeric species were detectable by EM 
(Figure 4.6 C). The sensitivity of EM is poor for oligomers and hence it is possible 
that there are more oligomers in the pH 9.0 condition within 30 min of aggregation. 
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Interestingly the number of oligomeric species increased along with fibrils. Even after 
120 h, we observed many small oligomeric species (arrowhead). AFM images of 
aggregates formed after 72 h at TBS pH 9.0 also displayed short fibrils (white arrows) 
and oligomers (white arrowhead) (Figure 4.6 F). This suggests that pH 9.0 favors the 
oligomers rather than fibrils and hence we chose TBS pH 9.0 conditions for oligomer 
preparation. 
4.4.3 Purification of oligomers by size exclusion chromatography 
The aggregation kinetics of TauRDΔ suggested that, at 30 min of aggregation there is 
an enrichment in small oligomers. Hence we chose the 30 min time point for the 
separation/purification of oligomers from the monomers and the prefibrillar forms of 
Tau aggregates. When testing gel filtration chromatography we observed that the 
initial aggregates are in a highly dynamic assembly/disassembly state and are 
therefore not separable on a superose PC 12 column. The protein eluted mostly as 
monomers in the chromatogram suggesting that the oligomers are not stable (Figure 
4.7 C). But we also observed a smaller amount of higher aggregates at ~0.8 ml of 
elution volume which corresponds to the molecular weight of >2000 kDa. Thus it 
appears that smaller oligomeric species are not stable in PBS pH 7.4 conditions 
whereas aggregates >2000 kDa might be stable. The marker proteins were loaded 
on the same Superose PC 12 column and the elution profile of marker proteins were 
used to compare the size of the TauRDΔ aggregates (Figure 4.7 A). 
We next checked TauRDΔ protein in the absence of DTT, because in the presence of 
DTT the oligomers might fall apart as DTT will reduce the disulfide bridges. 
Therefore, to prevent oligomer breakdown, we did not use DTT. Without DTT, higher 
molecular weight aggregates were pronounced in the elution profile. Monomers of 
TauRDΔ (13.6 kDa) were eluted at 1.6ml whereas higher molecular weight aggregates 
were eluted at 0.8ml corresponding to MW ~2000 kDa (or a multimers of ~150 
monomers). This indicates that some aggregates were already present in the sample  




Figure 4.7 Separation of Tau
RDΔ
 oligomers.  
A) Elution profile of the marker proteins on Superose PC 12 column. Mixture of blue dextran (2000 
kDa), ferritin (440 kDa), catalase (232 kDa), ovalbumin (46 kDa), and ribonuclease A (13.6 kDa) were 
mixed at 10µg/ml concentration and run on Superose PC 12 column. The elution profile of these 
mixtures serves as a reference. B) Tau
RDΔ
 protein was incubated in PBS pH 7.4 for 30 min without 
DTT. The chromatogram displays monomers at 1.6 ml and the higher aggregates (multimers) at 
0.8ml. C) Tau
RDΔ
 protein was incubated in PBS pH 7.4 for 30 min with 1mM DTT which caused the 
disappearance of the aggregates. No oligomers in the range of <200 kDa were observed in the 
chromatogram.  
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within 30 min of starting the aggregation (Figure 4.7 B). They could be considered as 
prefibrillar or amorphous aggregates since they do not show enhanced ThS 
fluorescence. We did not observe any peak in the range between 1 and 1.5 ml of 
elution in the chromatogram which suggests that the oligomers are not stable and are 
not separable by a superose PC 12 column. 
4.5 Stabilization of TauRDΔ oligomers 
Since the oligomers are not SDS stable and are not separable by chromatography 
columns, we next tried to stabilize the oligomers. It was shown earlier that the 
compound EGCG (a component of green tea) is able to induce the formation of off-
pathway oligomers of α-synuclein protein and also inhibits its aggregation 
(Ehrnhoefer et al., 2008, Bieschke et al., 2010). Therefore we checked the ability of 
EGCG to inhibit the Tau aggregation and to preserve oligomers once they have 
formed. 
4.5.1 Reduction of Tau aggregation by EGCG  
 
Figure 4.8 Reduction of aggregates of  Tau
RDΔ 
protein by EGCG 
Tau
RDΔ
 protein was incubated in PBS pH 7.4 for 24, 48 and 72 h at 37°C. In the absence of EGCG, 
Tau
RDΔ
 forms aggregates and shows increased ThS fluorescence intensity. With increasing 
concentration of EGCG, the ThS fluorescence intensity is greatly reduced. 
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We first performed the Thioflavin S assay to check whether the EGCG is able to 
inhibit the aggregation of TauRDΔ protein in vitro. In the absence of EGCG, TauRDΔ 
exhibits ThS fluorescence of 700 a.u. within 24 h of aggregation and thereafter 
remains steady (Figure 4.8). In the presence of EGCG, the aggregation is reduced in 
a concentration dependent manner for concentrations between 25µM to 200µM, 
judging by the reduction of ThS fluorescence (Figure 4.8). We also observed a time 
dependent decrease in the ThS fluorescence intensity. For example, at 50µM EGCG 
concentration there is a reduction of ThS positive aggregates in a time dependent 
manner.  
4.5.2 EM reveals that EGCG reduces fibril length and increases oligomers 
 





 protein was incubated with and without 200µM EGCG for 72 h in PBS pH 7.4. A) Tau
RDΔ
 
protein in the absence of EGCG shows twisted lengthy fibrils. B) Tau
RDΔ
 in the presence of EGCG 
displays reduced fibril length (black arrow) and more globular shaped oligomers or aggregates (arrow 
heads).  
 
Electron microscopy was employed to study the structural changes caused by 
EGCG. In the absence of EGCG, TauRDΔ protein aggregates into long twisted fibrils 
similar to Alzheimer PHFs and contains only few smaller oligomeric species. By 
contrast, in the presence of EGCG (200µM, 72h) we observed short fibrils with 
varying lengths and many globular shaped oligomers or aggregates. Taken together, 
the ThS and EM data suggest that EGCG prevents the smaller aggregates or 
oligomers to become filaments. 
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4.5.3 EGCG increases SDS resistant soluble TauRDΔ oligomers 
 
Figure 4.10 EGCG induces the formation of SDS stable soluble oligomers 
Tau
RDΔ
 protein was incubated with and without EGCG at an increasing concentration for 72 h in PBS 
pH 7.4. The samples were centrifuged at 100,000Xg (TLA 100.3 rotor) for 1 h to separate pellet and 
supernatant and run on a 17% SDS gel. A) Silver stained gel of sedimentation assay samples in the 
presence of EGCG. B) Coomassie staining of sedimentation assay samples C) The quantification of 
the gel B using Image J. Note: Insoluble aggregates of Tau
RDΔ
 are reduced and SDS stable soluble 
Tau
RDΔ
 species are increased in an EGCG concentration dependent manner. 
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TauRDΔ protein was incubated in PBS pH 7.4, 1mM DTT at 37°C for 72 h with or 
without EGCG at an increasing concentration. After 72 h of incubation, the samples 
were pelleted down by centrifugation at 100,000xg. The supernatant and the pellet 
fractions were analyzed on 17% SDS gels and stained with silver and Coomassie 
Blue. The pellet fractions contained the higher molecular weight aggregates (above 
~70 subunits)  and the supernatant fractions contained smaller aggregates, 
oligomers and monomers. 
By Coomassie staining ~20% of TauRDΔ was present in the pellet fraction in the 
control sample without EGCG decreasing to ~10% with EGCG, whereas the soluble 
supernatant fraction increased (Figure 4.10 B, C). The reduction of aggregates was 
also clearly visible in the gel pockets containing aggregates that did not move into the 
gel. A more detailed picture emerged when the samples were stained with silver 
(Figure 4.10 A), revealing that the majority of protein was in the supernatant fraction 
in the 200µM EGCG treated sample (Figure 4.10 A). The supernatant also revealed 
SDS stable soluble oligomers of low stoichiometry, mostly dimers and trimers of 
TauRDΔ which were not present without EGCG. Thus the sedimentation analysis 
suggests that EGCG promotes the formation of SDS-stable low-n oligomers. 
EGCG stabilized oligomers are not separable from monomers by Superose PC 12 
column (data not shown). In order to understand the oligomers in detail, a polyclonal 
antibody (by Eurogentec company, Belgium) was generated against the EGCG 
stabilized oligomers. Unfortunately, the generated antibody was not specific for 
oligomers analyzed by western and dot blot assays (data not shown). Therefore, we 
discontinued this approach and searched for alternative methods for stabilization of 
TauRDΔ oligomers. This lead us to test different methods of chemical cross-linking, 
focusing in particular on disuccinimidyl suberate (DSS) and glutaraldehyde (GA), as 
described in the following section. 
4.6 Stabilization of TauRDΔ oligomers by chemical cross-linking 
Glutaraldehyde is a common cross-linker used in biological microscopy. It has  
homo-bifunctional reactive groups at both ends which can react with amine groups of 
proteins, mainly lysine (Migneault et al., 2004).  
DSS is a noncleavable and membrane permeable cross-linker that contains an 
amine-reactive N-hydroxysuccinimide (NHS) ester at each end of an 8-carbon spacer 
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arm. NHS esters react with primary amines at pH 7-9 to form stable amide bonds, 
accompanied by the release of the N-hydroxysuccinimide leaving group (Mattson et 
al., 1993). Proteins, including antibodies, generally have several primary amines in 
the side chain of lysine (K) residues and the N-terminus of each polypeptide that are 
available as targets for NHS-ester cross-linking reagents. 
TauRDΔ protein was incubated in PBS pH 7.4 for 30 min to allow limited aggregation 
and then cross-linked with different concentrations of DSS and GA. At 0.125% 
concentration, glutaraldehyde cross-linked the protein after 5 min of incubation at 
37°C (Figure 4.11 A), without further increase in the band intensity at later times. The 
cross-linked protein contained low-n oligomers (dimers, trimers, tetramers at ~28 – 
42 kDa Mr values) and some higher order species visible as a smear in the stacking 
gel. We analyzed the potency of GA as a cross-linker and found that concentrations 
below 0.01% were not effective in cross-linking the protein. Between 0.01% and 
0.125% of GA there were no significant changes (Figure 4.11 B). These results 
suggest that GA cross-links the aggregates which are already present in the solution, 
and that a low level of 0.01% GA and 5 min of incubation is enough to cross-link the 
aggregates. 
Similarly, we tested the cross-linker DSS which had been used to cross-link Tau 
protein previously (Guttmann et al., 1995) The stabilization of Tau-Tau interactions 
with DSS indicated that intermolecular disulfide bonds likely play a predominant role 
in dimer formation, but the formation of higher order oligomers of Tau cannot be 
attributed to these bonds alone. 
DSS at concentrations as low as 0.1mM and at 30 min incubation at 37°C was able 
to cross-link mainly the higher order aggregates, as we did not observe any low-n 
oligomers in the SDS gel (Figure 4.11 C). As a control, to confirm the presence of 
low-n oligomers, we also loaded GA cross-linked oligomers on a gel. The sample 
without any cross-linker did not show any intermediate bands, as the oligomers were 
not SDS stable. However, there were higher order aggregates in the stacking gel 
which could be SDS stable aggregates (Figure 4.11 C).  




Figure 4.11 Stabilization of Tau
RDΔ
  oligomers by chemical cross-linking 
Tau
RDΔ
 protein was incubated in PBS pH 7.4 for 30 min at 37°C. A) Glutaraldehyde cross-linker at 
0.125% concentration was incubated for different time intervals up to 15 min. B) Incubation of Tau
RDΔ
 
with increasing concentrations of glutaraldehyde for 10 min at 37°C. C) Incubation of Tau
RDΔ
 oligomers 
with decreasing concentrations of DSS (0.5-0.1 mM) for 30 min. D) Incubation of Tau
RDΔ
 oligomers 
formed during 30 min of aggregation with 0.5mM DSS for different time intervals (2-30 min). In figure C 
and D, GA sample is used as a control to show different aggregates present in the same sample used 
for DSS cross-linking. GA -Glutaraldehyde, M -marker proteins. 
 
We next asked whether the DSS cross-linker forces the low-n oligomers into the 
higher-n aggregates during the incubation time. We incubated DSS cross-linker with 
the protein for short time periods and observed that within 2 min of incubation, DSS 
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cross-linked the protein aggregates, but not the low-n oligomers which were already 
present. At extended times, the cross-linker reacted with TauRDΔ more strongly and 
generated an intense higher molecular weight smear at 30 minutes of incubation 
(Figure 4.11 D). In conclusion, since DSS did not cross-link all the species of 
aggregates, we chose to use GA for further experiments. 
4.6.1 Separation of GA stabilized oligomers 
A major tasks of this project was to separate the oligomers from the monomers and 
fibrils. To achieve this, we incubated TauRDΔ protein at 50µM concentration in PBS 
pH 7.4 and TBS pH 9.0 for 30 min without DTT at 37°C. (TBS buffer at pH 9.0 
conditions reduced the fibril length and increased the oligomers and polymers which 
led us to choose this condition for oligomer preparation (Figure 4.6 D). The half-life of 
DTT is 9 h in PBS/TBS buffer. DTT breaks the disulfide bridge links between tau 
molecules. In order to avoid the disintegration of oligomers into monomers by DTT, 
we omitted DTT in our experiments; (Figure 4.7 C). The aggregated samples were 
cross-linked using 0.01% GA for another 10 min at 37°C and run on analytical 
Superose PC 12 column.  
We observed low-n oligomers of TauRDΔ already at 0 h which are formed during the 
sample preparation before the beginning of aggregation (Figure 4.12 A; arrow). 
When TauRDΔ protein was incubated for 30 min in PBS pH 7.4, we observed low-n 
oligomers and higher aggregates in a chromatogram (Figure 4.12 B; arrows). 
However, there was little difference in the oligomer content but more aggregates. A 
different picture emerged in conditions of TBS pH 9.0. There was an increase in the 
oligomer content compared to the conditions of PBS, pH 7.4 (Figure 4.12 D; arrow). 
This was confirmed by the gel analysis (Figure 4.12 E).  
The results suggest that the oligomers are highly stable in TBS pH 9.0. The fractions 
of FPLC (elution volume 0.8 to 1ml – Lane 3 & 4 and 1.2 to 1.6ml – Lane 5 to 14) 
were run on a 17% gel which shows the separation of oligomers from the monomers. 
Although the separation is not complete, we were able to separate more than 60% of 
the oligomeric protein from the monomers (Figure 4.12 E). These chromatography 
results together with aggregation kinetics results (especially light scattering and ANS 
(Figure 4.4) provided the rationale for generating oligomers of the  




Figure 4.12 Separation of oligomers stabilized by glutaraldehyde 
Tau
RDΔ
 protein was incubated in PBS pH 7.4 or TBS pH 9.0 buffer for 30 min at 37°C, then the sample 
was cross-linked with 0.01% GA for 10 min and run on a Superose PC 12 column. A) At 0 h, 
oligomers are observed at a low level (mostly dimers, trimers, and tetramers). B) At 30 min, oligomers 
and higher aggregates are present when incubated in PBS pH 7.4. C) 0 h sample cross-linked in TBS 
pH 9.0 buffer contains monomers, low-n oligomers and higher aggregates. D) Oligomers and 
aggregates increased after 30 min of aggregation. The peak filled with blue color represents the 
oligomeric fraction without monomers. The peak right to the dotted line represents monomers with little 
oligomers.   E) Representative silver stained SDS gel picture of fractions (Figure D) shows the 
separation of oligomers from monomers (Red box; lanes – 5 to 9). Lane 1 – Sample before HPLC; 
Lane 2 – Marker; Lane 3 & 4 – fractions with higher aggregates. 
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protein in TBS pH 9.0 without DTT. The next task was to upscale the production of 
TauRDΔ oligomers, as described below. 
4.6.2 Large scale purification of TauRDΔ oligomers by G200 column 
2 ml of TauRDΔ oligomers prepared in TBS pH 9.0 were injected into a Superdex G 
200 column for purification. The elution profile of this sample shows a merge of two 
peaks around 90 and 100 ml of elution. There was also a small peak at 40ml 
representing higher aggregates. From the chromatogram it is not evident whether the 
oligomers are separated from monomers (Figure 4.13 A and B). However, analysis 
on 17% SDS gels (silver stained) demonstrates that fractions eluted between 70-90 
ml contain primarily low-n oligomers; fractions between 90-100 ml contain both 
monomers and oligomers (Figure 4.13 C). The oligomers-only and mixed fractions 
were collected separately, concentrated, and analyzed on 17% SDS gels to check 
the stability of the oligomers. This showed that the oligomers are stable and GA 
cross-linking was intact (data not shown). These G200 purified TauRDΔ oligomers 
were used for further studies. 
 




Figure 4.13 Large scale production of oligomers using a G200 column 
Tau
RDΔ
 oligomers were run on a Superdex G 200 column to separate the oligomers from monomers. 
A) Representative chromatogram displaying the elution profile of Tau
RDΔ
 protein aggregated for 30 min 
and cross-linked with 0.01% GA. B) Magnification of the main peak from the chromatogram (A). The 
fractions from 70 to 100 ml (between dotted lines; shaded blue; fractions 36-43) contain only oligomers 
without monomer contaminations. C) The fractions were eluted and run on a 17% SDS gel and stained 
with silver. PS – Sample before FPLC, M – Marker, number denotes tube number of collected 
fractions.  
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4.6.3 Characterization of GA-stabilized oligomers purified by G200 column 
 
Figure 4.14 Characterization of oligomers purified by G200 column 
A) The oligomeric fractions of the sample show a moderate (~2-fold) increase in ThS intensity 
compared to the monomer fraction, but a much larger increase (~9-fold) for the fibril sample. B) ANS 
fluorescence shows a pronounced increase (~4-fold) both for the oligomeric fractions and fibrillar 
fractions. C) Circular dichroism spectra display negative maxima at ~200 nm (indicative of natively 
unfolded structure) for monomer, oligomer and fibril samples. D) AFM height image and (E) its 3D-
representation revealed oligomers corresponding roughly to 5-6nm (arrows). 
 
The biophysical and structural analysis included spectroscopic methods like CD and 
fluorescence. For example, the dye ThS binds to extended ß-sheet structures and 
responds by an increase in fluorescence. TauRDΔ monomers showed only minimal 
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fluorescence, oligomers showed only a slight increase, but both were negligible 
compared to the ThS response of fibrils. This suggests that there is only minimal ß-
sheet structure in the oligomeric fractions (Figure 4.14 A). Circular dichroism spectra 
confirmed that there is only minimal ß-sheet structure in oligomers, as the negative 
maximum was at ~200 nm, characteristic of random coiled structure. A similar pattern 
occurred in the fibrillar sample, indicating that the major part of the protein is 
unstructured. This could be due to the fact that TauRDΔ protein has only a few amino 
acids around the hexapeptide motifs in the R2 and R3 region to form ß-sheet 
structure (Figure 4.14 C). Whereas ThS reports on ß-sheet structure of a protein 
locally, CD is sensitive to the protein structure as a whole, which would explain the 
difference in the outcome by these two methods. Contrary to ThS, the dye ANS 
displayed a 4-5 fold increase in the fluorescence intensity in the oligomeric fraction 
compared to monomers, suggesting hydrophobic patches and/or cationic residues on 
the surface of the oligomers exposed by conformational changes (Figure 4.14 B). A 
similar increase occurred in the fibril sample. The dyes ThS and ANS show markedly 
different reactions with regard to oligomers and polymers of Tau. Finally, AFM 
demonstrates that the oligomers are roughly globular in shape, with a height less 
than 8nm (~7-8 monomers), consistent with low-n oligomers. (Figure 4.14 D and E; 
arrows). 
4.6.4 Selection of the hydrophobic interaction chromatography column 
After the preliminary characterization of the oligomers, the major concern was to 
enhance the amount of oligomers, as the G200 column was able to purifiy only ~50% 
of the total oligomeric protein. The reason is that substantial amounts of oligomers 
were needed for further characterization and for antibody generation. Therefore we 
searched for other methods to purifiy oligomers.  
One hint was provided by the observation that TauRDΔ oligomers contain exposed 
hydrophobic microdomains as suggested by the increase in ANS fluorescence. This 
prompted us to apply hydrophobic interaction chromatography (HIC) to separate the 
oligomeric species from the monomers. We used the HIC selection kit (GE 
Healthcare) to identify a suitable column for oligomer separation. The selection kit 
comprises seven columns with different hydrophobicities. During the HPLC run, the 
hydrophilic molecules do not bind to the column and elute earlier in the flow-through 
whereas the bound hydrophobic proteins elute later. 1M ammonium sulfate 
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(NH4)2SO4 buffer was used as an adsorption buffer which improves the binding of the 
hydrophobic protein to the column. A gradient of TBS pH 9.0 /water was used as an 
elution buffer. A decreasing concentration of salt reduces the interaction of the 
protein with the hydrophobic column matrix and thus allows detachment of the protein 
from the column.  
The tests showed that the Butyl FF HiTrap 1ml column is able to separate the 
oligomers with high purity. The strongly hydrophilic TauRDΔ monomers did not bind to 
the column and eluted in the flow-through, whereas the more hydrophobic oligomers 
eluted later in the middle of the gradient (Figure 4.15 C). The silver stained gel 
picture illustrates that the flow-through contains only the monomer (Figure 4.15 D; 
red arrow). The quantification of the silver gel revealed that ~5% monomers were still 
present in the fractions so that oligomers (only low-n) were separated with a purity of 
~95%. Similarly, other columns, e.g. the Phenyl Sepharose HP column was able to 
separate the oligomers with high purity, except that the recovery was lower (< 70%) 
(Figure 4.15 E). The Butyl Sepharose HP column was also able to separate the 
oligomers, but a fraction of oligomers eluted in the flow-through which made this 
column unsuitable for the oligomer preparation (Figure 4.15 A; red oval box). Similar 
results were obtained with the Phenyl FF column (Figure 4.15 H; red oval box). Three 
further columns were also tested but did not separate the oligomers from the 
monomers. The characteristics of the columns used and the results of the 
experiments are summarized in Table 4.1. For further work we used the Butyl FF 
column for purification of TauRDΔ oligomers. 
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Table 4.1 Purification of Tau
RDΔ
 oligomers by hydrophobic interaction chromatography (HIC) 
4.7 In vitro Characterization of TauRDΔ oligomers 
4.7.1 Large scale preparation of TauRDΔ oligomers 
TauRDΔ monomers (0 h) were diluted in TBS pH 9.0 and ran on a Butyl FF 16/10 
column. The protein did not bind to the column although a high salt buffer was 
present as an adsorption buffer. Since TauRDΔ monomers are highly hydrophilic they 
did not bind to the column and hence the protein was collected as flow-through 
(Figure 4.16 A).  
Figure 4.15  Selection of the hydrophobic interaction chromatography column 
Tau
RDΔ
 protein was incubated at 37°C for 30 min in TBS pH 9.0 and cross-linked with 0.01% GA for 10 
min. The reaction was stopped by 10mM Tris HCl pH 8.8. The samples were run on the 1ml HiTrap 
HIC columns to select the suitable column for oligomer purification. The samples were adsorbed in the 
column by 1M NH4(SO4)2 and eluted in 20 column volume of buffer with an increasing concentration of 
buffer B (H2O) and reducing concentration of buffer A (TBS pH 9.0). The black arrows on the 
chromatogram show the oligomeric peak. The oligomeric peak fractions were run on a 17% SDS gel 
along with the flow-through sample and stained with silver. (A) The chromatogram of Butyl Sepharose 
HP column and (B) the respective silver stained SDS gel picture. (C) The chromatogram of Butyl FF 
column and (D) the respective silver stained SDS gel picture. (E) The chromatogram of Phenyl 
Sepharose HP column and (F) the respective silver stained SDS gel picture. (G) The chromatogram of 
Phenyl Sepharose FF column and (H) the respective silver stained SDS gel picture. PS – Sample 
before the HPLC run; FT – Flowthrough (red arrows on the gels); M – Marker; numbers on the top of 
the gels denote the fraction tube numbers in which the proteins were collected. 
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The next experiment shows TauRDΔ protein incubated in TBS pH 9.0 buffer at 37°C 
for 30 min and then cross-linked with 0.01% GA (oligomer sample) and run on the 
Butyl FF 16/10 column. As shown in Figure 4.16 B, the hydrophilic monomers eluted 
in the flow-through fractions, oligomers eluted in the middle of the gradient using the 
gradient buffer of TBS pH 9.0 / water. Decreasing the salt concentration by water 
released the oligomers from butyl ligand of the column. When using 1M (NH4)2SO4 
and TBS pH 9.0 as elution buffer it was not possible to elute the oligomers in the 
middle of the gradient, indicating a strong interaction of TauRDΔ oligomers with the 
butyl ligand of the column (data not shown). Finally we also checked whether a low 
concentration of adsorption buffer reduces the binding of the oligomers to the 
column. However, reducing the concentration of (NH4)2SO4 to 0.5M in the adsorption 
buffer caused no binding of oligomers to the column (Figure 4.16 C). Therefore we 
conclude that the TauRDΔ oligomers can be separated by Butyl FF 16/10 column only 
with a high concentration of (NH4)2SO4 as an adsorption buffer followed by TBS pH 
9.0 + water gradient as an elution buffer. This experiment further confirms the 
presence of hydrophobic residues on the surface of TauRDΔ oligomers. 




Figure 4.16 Large scale preparation of Tau
RDΔ
 oligomers by Butyl FF 16/10 column 
1M NH4(SO4)2 was used as an adsorption buffer and a TBS pH 9.0 / water gradient was used as an 
elution buffer. A) Tau
RDΔ
 monomers were run on Butyl FF 16/10 column. The hydrophilic monomers 
did not bind to the column and get eluted in the flow-through. B) The fractions were analyzed by SDS 
gel and stained with silver. C) Cross-linked Tau
RDΔ
 oligomers (30 min aggregation at 37°C and cross-
linked) bound to the column and eluted in the TBS/ water gradient (in the middle of the gradient). D) 
The fractions were analyzed by SDS gel and stained with silver. E) Cross-linked Tau
RDΔ
 oligomers 
were run through the column with 0.5M (NH4)2SO4 adsorption buffer. The chromatogram shows that 
the oligomers did not bind to the column. F) The fractions were analyzed by SDS gel and stained with 
silver. Note: Tau
RDΔ
 oligomers can be separated by Butyl FF 16/10 column only with a high 
concentration of (NH4)2SO4 as an adsorption buffer followed by TBS pH 9.0 + water gradient as an 
elution buffer. 
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4.7.2 TauRDΔ oligomers undergo structural changes without ß-structure 
 





 oligomers were concentrated and buffer exchanged to PBS pH 7.4. A) Oligomers do 
not enhance ThS fluorescence, indicating a low content of ß-sheet structure. B) ANS fluorescence 
shows that the purified oligomers display an increase in ANS fluorescence due to surface exposed 
hydrophobic microdomains, confirming a conformational change in Tau
RDΔ
 during oligomerization. C) 
CD spectroscopy shows that monomers, oligomers and fibrils are all dominated by random coil 
structure (negative maximum at ~200 nm). 
 
The TauRDΔ oligomers were concentrated by centrifugation using 3000 MWCO filters 
and the buffer was exchanged to PBS pH 7.4. Next we used ANS fluorescence to 
assess whether TauRDΔ oligomers underwent a structural rearrangement. Since 
monomers are hydrophilic, they do not bind to the ANS dye strongly. TauRDΔ 
oligomerization leads to an increase in ANS fluorescence up to 4-5 fold. A similar 
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increase occurred in the fibril sample of TauRDΔ (Figure 4.17 B) indicating that fibrils 
also have similar level of hydrophobicities as oligomers.  
In order to investigate the contribution of ß-sheet structure which has been shown to 
be necessary to cause toxicity in the TauRDΔ cell and animal models, thioflavin S 
(ThS) and circular dichroism (CD) measurements were performed. We observed that 
there was a slight increase in the ThS intensity in the fractions containing pure 
oligomers compared to the monomer. However, when compared to fibril sample, the 
ThS intensity observed in oligomers was insignificant (Figure 4.17 A). 
Changes in the secondary structure of oligomers were measured by CD analysis.  
TauRDΔ monomers showed the spectral minimum at 198 nm which is the typical 
absorption spectrum of a randomly coiled and natively unfolded protein structure. At 
the same wavelength (198 nm) TauRDΔ oligomers and TauRDΔ fibril also absorbed the 
maximum of circularly polarized light (Figure 4.17 C). The data obtained from ThS 
fluorescence and CD analyses suggest that TauRDΔ oligomers have a low content of 
beta sheet structure. In summary, the TauRDΔ oligomers undergo structural 
rearrangements without adopting ß-sheet conformation. The above data also confirm 
that the properties of TauRDΔ oligomers were not altered by Butyl FF 16/10 column.  
4.7.3 Atomic force microscopy reveals globular TauRDΔ oligomers  
The biophysical and biochemical characterization reveal that the protein undergoes 
structural rearrangements during oligomerization. The morphology of the TauRDΔ 
oligomers was analyzed by atomic force microscopy. TauRDΔ oligomers appear as 
punctate structures in height images (Figure 4.18 A). The amplitude images clearly 
distinguish the edges from the surface of the mica, arguing that the oligomers have a 
roughly globular shape (Figure 4.18 C). The 3-dimensional view of the height image 
precisely demonstrates the height of the oligomers (Figure 4.18 B).  The observed 
height of the oligomers ranges from 1.6 nm to 15 nm (Figure 4.18 D) with an average 
of 3.7±1.9 nm. The majority of the oligomers (approximately 90%), have heights 
between 1.6 nm to 5.4 nm (corresponding to dimers up to hexamers), and only a few 
were >10nm (corresponding to 15-20 tau molecules).  









 oligomers purified by the Butyl FF 16/10 column were imaged by atomic force microscopy in 
oscillation mode of imaging. A) Height image shows punctate structures ranging from 2 nm to 15 nm. 
B) 3D representation of the height image displays the height of the oligomers. C) Amplitude image 
shows globular shaped oligomers. D) Quantification of height of the Tau
RDΔ
 oligomers by nanoscope III 
software.  
 
The average height of the monomer of TauRDΔ is not accurately known, as this 
protein does not stay in the monomeric state and also TauRDΔ monomers do not have 
a specific conformation. At early time points of oligomerization the average height is 
about 3.2±0.1 nm. For monomeric TauRD the height was reported as 1-2 nm (Kumar 
S.et.al 2014). Hence comparing with the TauRD monomers, the average size of the 
TauRDΔ oligomers appears to contain approximately 4-5 molecules of TauRDΔ. This is 
broadly consistent with the SDS gel analysis showing predominantly dimers, trimers 
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and tetramers of TauRDΔ (Figure 4.16 B). These observations confirm that the 
oligomers formed by this specific preparation method are primarily low-n oligomers. 
4.7.4 Hydrodynamic radius of oligomers  
 
Figure 4.19  Hydrodynamic radius of Tau
RDΔ
 oligomers  
The hydrodynamic radius of Tau
RDΔ
 monomers and oligomers were measured by dynamic light 
scattering. The samples were thermally equilibrated for 2 min before measurements were taken. 
A) Tau
RDΔ
 monomers and oligomers displayed the hydrodynamic radius of ~3nm and ~5-6 nm 
respectively.  (B) The histogram shows that average of hydrodynamic radius of multiple experiments.  
 
Next, we analyzed TauRDΔ oligomers by dynamic light scattering (DLS) which yields 
the effective hydrodynamic radius deduced from the fluctuations of scattered light. 
The average hydrodynamic radius of TauRDΔ monomers is 3.17±0.19 nm, in the case 
of oligomers it increases about 2-fold to 5.23±1.03 (Figure 4.19 A, B). This average 
value corresponds effectively to a stoichiometry of n=4, consistent with the mixture 
observed in SDS gels. 
4.8 Functional characterization (extracellular effects) of TauRDΔ oligomers  
A major question in the field of Tauopathies is whether Tau oligomers are toxic. In 
case of other amyloidogenic oligomers like Aß oligomers the toxic effects were 
shown to be strongly assay dependent (Wogulis et al., 2005)  and the mechanism of 
toxicity and the nature of the toxic species are still a matter of debate. Thus, to make 
results comparable and to avoid false positive results, we first standardized the 
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methods to analyze the toxicity of the oligomers. TauRDΔ oligomers do not cause cell 
death in neuronal cell culture 
4.8.1 TauRDΔ oligomers do not cause cell death in cell culture models 
We tested 4 different assay systems to analyze the toxic properties of oligomers. In 
order to standardize the assay, the monomers and oligomers of TauRDΔ were 
incubated for different time intervals (24 h and 48 h), at different concentrations 
(1µM, 5µM and 10µM), using both SH-SY5Y human neuroblastoma cells and primary 
cortical neurons.  
(1) The lactate dehydrogenase (LDH) assay of cell viability measures the LDH level 
in the cell culture medium, as the affected cells will lose their membrane integrity and 
increase the LDH level in the medium. Thus the amount of LDH in the medium is 
directly proportional to the amount of dead cells. The positive control (rupturing of 
membranes by Triton X-100) showed a clear increase of LDH, but samples treated 
with TauRDΔ for different periods and concentrations showed no release of LDH 
above background. Thus, judging by the standard LDH release assay TauRDΔ 
monomers and oligomers do not affect the membrane integrity of the cell and 
therefore show no detectable toxicity (Figure 4.20 A and B). 
(2) A second parameter of toxicity is metabolic activity of the cells which can be 
measured by the reduction of MTT which is achieved by metabolically active cells 
and is therefore indirectly proportional to the dead cells. As controls, there was a 
pronounced loss of cell viability in cells treated with Triton X-100 (disrupting 
membranes). However, there was no change in cells treated with TauRDΔ monomers 
or oligomers (Figure 4.20 C and D). A variant of it is the XTT assay which measures 
the pyridine nucleotide redox status of cells controlled by the mitochondrial 
oxidoreductase. Consistent with the MTT assay, there was no change in the 
monomer and oligomer treated cells for both SH-SY5Y cells and rat primary cortical 
neurons (Figure 4.20 E and F).  
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Figure 4.20 Selection of assays for Tau-induced cell toxicity 
The monomers and oligomers of Tau
RDΔ
 were incubated for different time intervals (24 h and 48 h), at 
different concentrations (1µM, 5µM and 10µM) with both SH-SY5Y cells (left panels) and rat primary 
cortical neurons (right panels). The toxic effects were monitored by LDH, MTT, XTT and Alamar blue 
(AB) assays. (A-B) LDH release assay, (C-D) MTT assay, (E-F) XTT assay, (G-H) Alamar Blue assay. 
Note that there is no difference between the untreated cells and Tau
RDΔ
 oligomer treated cells in all the 
assays. The MTT and LDH assays were chosen to measure toxicity in cell culture systems. Untr – 
Untreated; Tx-100 – Triton X-100 (2%). 
 
(3) As a further criterion we used the Alamar Blue assay of cell viability. Upon 
entering cells, resazurin is reduced to resorufin, which produces a bright red 
fluorescence when it reacts with Alamar Blue. Viable cells continuously convert 
resazurin to resorufin, thereby generating a quantitative measure of viability or 
conversely, cytotoxicity. Consistent with the other methods, the Alamar Blue assay 
illustrates that monomers and oligomers are not toxic to the cells. (Figure 4.20 G and 
H).  In summary, because of the differences in the responses to XTT and Alamar 
Blue, we decided to follow the MTT and LDH as a measure of toxicity. 
Since the TauRDΔ oligomers are cross-linked, we also looked at the viability of the 
cells when treated with unpurified TauRDΔ oligomers which are formed from 
monomers after 30 minutes of incubation at 37°C without and with GA cross-linking. 
These unpurified oligomers in the non-cross-linked state or cross-linked state are 
also not toxic to rat primary neuronal cells analyzed by MTT and LDH assays (Figure 
4.21 A, B). Similarly, the effects of non-cross-linked oligomers prepared in PBS pH 
7.4 buffer were analyzed in SH-SY5Y cells without revealing toxicity by MTT assay 
(Kumar et al., 2014). 
We also used several other controls (buffer from column, BSA, BSA cross-linked) to 
prove that GA neither induces toxicity nor blocks the toxic effects of a protein. We 
cross-linked bovine serum albumin (BSA, whose amino acid composition resembles 
that of Tau protein) at similar concentrations and applied it to SH-SY5Y cells. We did 
not observe any toxicity in cells treated with BSA or crosslinked BSA (Figure 4.21 C).  
 




Figure 4.21 GA does not block the Tau
RDΔ
  mediated toxicity 
Tau
RDΔ
 protein was incubated in TBS buffer, pH 9.0 for 30 min at 37°C. The sample was cross-linked 
with 0.01%GA and some portion was not cross-linked. The unpurified non-cross-linked and cross-
linked oligomers were applied to rat primary hippocampal neurons for 24 h and the toxicity was 
analyzed by MTT (A) and LDH (B) assays. Results show that the non-cross-linked and cross-linked 
oligomers are not toxic to the neurons. (C) GA neither induces nor blocks the toxicity which was 
analyzed by MTT assay using other proteins like BSA and several buffer controls 
 
In summary, all these results suggest that TauRDΔ oligomers are not toxic to the 
neuronal cell culture models and that crosslinking of TauRDΔ by GA does not alter the 
response of cells to TauRDΔ.  
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 oligomers do not cause cell death in the OHSC model 
Hippocampal slices were prepared from 8 days old wild type mice and cultured for 11 days in vitro.  
Tau
RDΔ
 monomers and oligomers (1µM and 10µM) were incubated with the slices for 48 h. A) NeuN 
staining revealed that there was no neuronal loss in CA1, CA3 and DG of the hippocampus. B) There 
was no change in the neuronal number in all regions of the hippocampus (CA1, CA3 and DG). C) 
There was no increase in the LDH release in the oligomer and monomer treated slices compared to 
untreated slices. 
 
Organotypic hippocampal slice cultures (OHSCs) represent an ex vivo method to 
examine mechanisms of neuronal injury. The advantage of OHSCs is that the basic 
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architecture and composition of the hippocampus is relatively well preserved. It was 
shown earlier that the TauRDΔ expressing mice display loss of neurons in the CA3 
and other regions of the hippocampus (Mocanu et al., 2008, Messing et al., 2013). 
We reasoned that microglia and other cell types in the hippocampus might act as 
mediators for the cytotoxicity caused by TauRDΔ protein, which could explain why 
cytotoxicity was not observed in the cell culture system, and hence we utilized the 
OHSC model. OHSCs were prepared from p8 wild type mice and cultured for 11 
days. TauRDΔ oligomers were applied on slices for 48 hours and the toxicity was 
measured by LDH release and total neuron counting. The LDH release assay 
showed that TauRDΔ oligomers did not cause any significant toxicity or cell death in 
slices even at higher concentrations (10µM) compared to monomer and buffer 
treated slices (Figure 4.22 C). Consistent with this, NeuN staining of the slices fixed 
after 48 hours of treatment with TauRDΔ oligomers revealed that there was no 
reduction in the neuronal number in all regions of the hippocampus (CA1, CA3 and 
DG) (Figure 4.22 A, B), suggesting that TauRDΔ oligomers do not cause cell death in 
the OHSC model as well. 
4.8.3 Aggregation intermediates of full length Tau are not toxic 
In the literature there have been claims that Tau oligomers prepared from full length 
Tau protein by different methods are highly toxic to the SH-SY5Y cell system 
(Lasagna-Reeves et al., 2010, Flach et al., 2012). We therefore checked the toxicity 
of aggregates of recombinant human full length Tau protein (ht40 wt) formed under 
different buffer conditions in the presence of heparin 16,000 at different time points. 
The presence of aggregates was confirmed by ThS and ANS fluorescence 
measurements (data not shown). In our hands, these aggregated Tau species 
formed in different conditions did not show any significant release of LDH when 
applied on the differentiated SH-SY5Y cells (Figure 4.23 B), and they did not show a 
significant reduction in cell viability by the MTT assay (Figure 4.23 A). This argues 
that wild type full-length Tau monomers and aggregates are not toxic to SH-SY5Y 
cells when present in the extracellular medium and suggests that the toxicity is not 
dependent on the domains of Tau. 






 aggregation intermediates are not toxic to SH-SY5Y cells 
Full length wild type recombinant Tau protein (2N4R) was aggregated in MOPS pH 7.0 and BES pH 
7.0 buffers in the presence of heparin 16000 (protein to heparin ratio = 4:1). The aggregates formed at 
different time points were applied to the cell culture medium (7.5 µM for 48 h) on SH-SY5Y cells and 
the cytotoxicity was measured by LDH (B) and MTT (A) assays. No significant amount of LDH release 
or  MTT reduction was observed after exposure of cells with full-length Tau aggregates  
 
4.8.4 TauRDΔ oligomers cause loss of spines and postsynaptic proteins 
Since TauRDΔ oligomers did not cause cell death to the neuronal cell culture and 
OHSC models, we focused on morphological changes in rat primary hippocampal 
neurons. We incubated TauRDΔ (monomers or oligomers) at 1µM concentration with 
rat primary hippocampal neurons (DIV 21) for 3 h. After 3 hours the cells were fixed 
and stained with phalloidin red which stains the actin filaments, a marker of spines, 
projecting away from dendritic shafts. Dendritic spines serve as a storage site for 
synaptic strength and help transmit electrical signals to the neuron's cell body. Most 
spines have a bulbous head (the spine head), and a thin neck that connects the head 
of the spine to the shaft of the dendrite. The most notable classes of spine shape are 
"thin", "stubby" and "mushroom". Spines with strong synaptic contacts typically have 
a large spine head (mushroom spines), which connects to the dendrite via a 
membranous neck. We observed up to 50% loss of spines in TauRDΔ oligomer treated 
cells compared to monomer treated cells. Moreover the majority of spines in the 
oligomer treated cells were of the "stubby" type (Figure 4.24 A arrow), whereas the 
PBS and monomer treated cells show mixture of thin, stubby and mushroom head 
spines. For quantification, the lateral projections of dendrites were counted as spines  










 oligomers reduce spine number and postsynaptic proteins 
Rat primary hippocampal neurons (DIV 21) were treated with Tau
RDΔ
 oligomers (1µM) for 3 h. The 
cells were fixed and stained with phalloidin red which stains the actin filaments a major component of 
spines. A) A representative image shows the presence of spines; Cultures treated with PBS buffer and 
Tau
RDΔ
 monomers reveal no changes in the spine density whereas Tau
RDΔ
 oligomer treatment reduces 
the spine density up to 50%. Note that the Tau
RDΔ
 oligomer treated samples displayed more stubby 
spines (arrow). B) Quantification of spine density; **** p value <0.0001. C) Tau
RDΔ
 oligomers 
dependent loss of spines; **** p value <0.0001. D) Western blot analysis of postsynaptic proteins in 
the Tau
RDΔ
 oligomer treated samples (red circle). E) Quantification of D shows a significant reduction 
of post synaptic proteins PSD 95, GluR1 and Drebrin (pink shaded box).  
 
whose head diameter was >1µm. Normal dendrites contain 1 spine/µm length. 
(Figure 4.24 A and B). Finally as shown earlier, there was no reduction in the spine 
numbers in the fibril treated samples (data not shown; See (Kumar et al., 2014).  
TauRDΔ oligomers cause loss of spines at concentrations as low as 100nM. For 
comparison, 1µM Aß oligomers caused a spine reduction of ~30% (Zempel et al., 
2010), comparable to that observed with 100nM of TauRDΔ oligomers. Lower 
concentrations (e.g. 10nM of TauRDΔ oligomers) did not lead to statistically significant 
changes (Figure 4.24 C). 
To corroborate the findings we investigated the level of postsynaptic proteins in 
oligomer treated cells. PSD-95, a marker of postsynaptic spines, decreased up to 
50% in the TauRDΔ oligomer treated cells, compared to buffer and monomer treated 
cells.  Similarly, the GluR1 subunits of AMPA receptors decreased in the oligomer 
treated samples up to 70%; they are characteristic of mature spines and necessary 
for LTP and calcium signaling. Drebrin, a neuronal actin-binding protein involved in 
spinogenesis and synaptogenesis, was decreased by up to 50% consistent with the 
reduced number of spines (Figure 4.24 D and E). 
4.8.5 TauRDΔ oligomers increase intracellular reactive oxygen levels  
There are several reasons for selective spine loss in the absence of overt cell death, 
one of them being increased stress conditions (Chen et al., 2008) (Zempel et al., 
2010). To test this, we determined the levels of reactive oxygen species as a 
measure of stress in the rat primary hippocampal neurons upon addition of TauRDΔ 
oligomers. If the level of ROS is increased the dye DCFDA becomes oxidized and 
converted to DCF which serves as a reporter of ROS. 






oligomers increase the intracellular ROS production 
Rat primary hippocampal neurons of 3-4 weeks old cultures were treated with Tau
RDΔ
 oligomers at 
different concentrations. Changes in the intracellular ROS level was monitored by live imaging using 
the DCFDA dye (the fluorimetric ROS sensor dye). A) Image displayed the ROS level at 0 time point 
or basal level which increases within 2 minutes of Tau
RDΔ 
oligomer addition and extends up to 20 
minutes. The white arrows show the same cells at 2 minutes and 20 minutes time points which show 
time dependent increase in ROS. (B) Quantification of ROS level in a complete field, as the increase 
in the ROS level was observed in the whole culture including dendrites and axons. Note: There was a 
Tau
RDΔ
 oligomer concentration dependent increase in the ROS level in mature rat primary 
hippocampal neurons. The transitory hump immediately after protein addition could be due to slight 
mechanical disturbance of the sample.  
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We observed that there was TauRDΔ oligomer concentration dependent increase in 
the ROS production in the mature rat primary hippocampal neurons (Figure 4.25 B). 
Oligomers as low as 1µM were able to increase the DCF fluorescence up to 15%, 
rising up to 50% at 10µM oligomers. By contrast, monomers of TauRDΔ even at 10µM 
concentration did not cause any significant increase. The maximum fluorescence 
intensity of DCF within 2 minutes of incubation occurred in all cell compartments. 
These observations argue that TauRDΔ oligomers cause the production of ROS in rat 
primary hippocampal neurons.  
Although overall, the ROS level reaches a maximum in 2 min, there are a few cells 
that show a time dependent increase in the ROS level reaching a maximum in ~20 
min of incubation (Figure 4.25 A; white arrows). By contrast there was no or only a 
minor increase in the ROS level in the buffer control and monomer control treated 
cells. We conclude that TauRDΔ oligomers cause the production of ROS in rat primary 
hippocampal neurons.  
4.8.6 TauRDΔ oligomers increase intracellular calcium levels  
Calcium homeostasis is important to regulate the signaling in a cell. Therefore we 
next checked the calcium homeostasis of rat primary hippocampal neurons treated 
with TauRDΔ oligomers using the ratiometric dye fura-2 by live imaging. Fura-2 in its 
free form absorbs light at 380 nm and emits at 516nm. The excitation wavelength will 
be shorter (340 nm) when the dye binds to calcium. The ratio of 340 to 380 nm in 
TauRDΔ oligomer treated cells showed a steady concentration dependent increase in 
the intracellular calcium. The maximum signal was reached at 20 minutes of 
incubation with oligomers (10µM) and occurred in all cell compartments (Figure 4.26 
A arrow).  By contrast, there was no significant increase in the calcium level in the 
TauRDΔ monomer incubated cells even at higher concentration (10µM) (Figure 4.26 
B). Interestingly, we saw up to 40% increase in the fura-2 calcium bound form in the 
cell body alone and the remaining percentage of increase must be from other 
compartments of a cell (Figure 4.26 C). These observations suggest that TauRDΔ 
oligomers increase the intracellular calcium level in the rat primary hippocampal 
neurons. 
  






oligomers increase the intracellular calcium level 
Rat primary hippocampal neurons of 3-4 weeks old cultures were treated with Tau
RDΔ
 oligomers at 
different concentration and changes in the intracellular calcium level were monitored by Fura 2 
ratiometric dye by live imaging. A) Image displays the calcium level at 0 time point or basal level 
which increased gradually and saturated in 20 minutes when Tau
RDΔ
 oligomers were applied. The 
white arrow at 10 minutes shows the increase of calcium in the dendrites and calcium and the white 
arrow at 20 minutes show that the cell bodies of Tau
RDΔ
 treated cells are filled with calcium B) 
Quantification of intracellular calcium level in a complete field, as the increase in the ROS level was 
observed in the whole culture including dendrites and axons. Note: There is a Tau
RDΔ
 oligomer 
concentration dependent increase in the ROS level in mature rat primary hippocampal neurons. C) 
Quantification of calcium solely in the cell bodies also showed an increase in the intracellular calcium 
level. 
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 oligomers do not cause phosphorylation and missorting of endogenous Tau 
Tau
RDΔ
 oligomers were incubated with primary rat hippocampal neurons (DIV 21) for 3 hours and then 
the cells were fixed and immunostained for the following antibodies K9JA (detects total Tau), 12E8 
(detects the phosphorylation of Tau at KXGS motifs), Phalloidin CF405 (dye binds to actin) and MAP2 
antibody (dendritic marker). A) There is no increase in the intensity of 12E8 antibody signal in 
oligomer treated cells compared to buffer control B) There is no missorting of Tau cells treated with 
buffer or oligomers (Tau+MAP2). Missorting of endogenous Tau is not necessary for reduction in 
spine density. However, severe spine loss occurs in oligomer treated cells and those dendrites do not 
reveal increased levels of endogenous Tau. 
Tau protein is primarily an axonal protein. During disease and stress conditions, it 
can become missorted into the dendrites of a neuron and phosphorylated at several 
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sites (Zempel et al., 2010, Zempel et al., 2013). We therefore investigated whether 
TauRDΔ oligomers also cause the phosphorylation and missorting of endogenous Tau. 
TauRDΔ oligomers were incubated with primary rat hippocampal neurons (DIV 21) for 
3 hours and then the cells were fixed and immuno stained for 12E8 (KXGS motifs 
phospho tau antibody), K9JA (total Tau antibody) and MAP2 antibody (marker for 
dendrites). We did not observe any significant increase in the intensity of 12E8 
antibody in the TauRDΔ oligomer treated sample suggesting that there is no 
phosphorylation of Tau at KXGS motifs (Figure 4.27 A). We also checked the 
phosphorylation of Tau at other sites (e.g. using the antibody AT8) and did not 
observe an increase in the phosphorylation (data not shown). 
We next performed double immunostaining with MAP2 and K9JA antibody to test the 
missorting of Tau, but this was not observed, as we did not observe co-localization of 
K9JA antibody (Tau) and MAP2 antibody (dendrites). Tau protein was present only in 
the axons, not in the cell body and dendrites. (Figure 4.27 B), even though there was 
a reduction in the spine density in the oligomer treated samples (Figure 4.27 B) 
compared to buffer control. This observation suggests that missorting of endogenous 
Tau is not essential for the spine loss in TauRDΔ oligomer treated cells. 
4.8.8 TauRDΔ oligomers act as seeds for intracellular Tau aggregation 
It is an open question whether TauRDΔ oligomers present in the extracellular medium 
induce the aggregation of intracellular Tau. Therefore, we applied the TauRDΔ protein 
(monomers and oligomers) directly on the cell culture medium of SH-SY5Y cells at 
different concentrations for 15 h and the aggregation of Tau was monitored by ThS 
positive cells using flow cytometry. As shown in Figure 4.28 f, TauRDΔ oligomers 
treated cells displayed a very low percentage of ThS positive cells (0.115%) when 
applied extracellularly. We also observed that there is a 2 fold increase in the ThS 
positive cells in the TauRDΔ oligomers treated cells (0.115%) compared to monomer 
treated cells (0.055%) (Figure 4.28 c and f).  The fact that the anti-aggregant mutant 
TauRDΔ-PP monomers did not show any increase in the ThS positive cells compared to 
untreated samples confirms that anti-aggregant mutant does not aggregate and does  




Figure 4.28 Extracellular  Tau
RDΔ
 oligomers act as seeds 
Tau
RDΔ
 proteins were applied directly on the SH-SY5Y cells for 15 hours. 1 h prior to the 15 h of 
incubation, 0.0005% ThS dye was added for 1 h and then ThS positive cells were counted using flow 
cytometry. Oligomers at 5 and 10µM concentration (e and f) showed very small percentage of ThS 
positive cells but higher than the monomer treated cells (c). There was a ~2-fold increase in the ThS 
positive cells in oligomer treated cells (0.115%) (Red box) compared to monomer treated cells 
(0.055%). Note: Anti-aggregant Tau (g) does not show ThS positive cells, similar to untreated cells. (h) 
Histogram summarizing ThS positive fractions in the different conditions. 
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not induce the aggregation of endogenous Tau protein. Hence this result suggests 
that extracellular TauRDΔ oligomers can act as seeds to some extent. 
4.9 Intracellular effects of TauRDΔ oligomers  
4.9.1 TauRDΔ oligomers aggregate into filaments after transfection into SH-
SY5Y cells 
Since Tau is an intracellular protein and the aggregation of Tau occurs inside the 
cells during disease conditions, we delivered the TauRDΔ oligomers directly inside the 
cells (SH-SY5Y and rat primary hippocampal neurons) using Xfect protein 
transfection reagent.  
The aim was to understand the toxic properties of TauRDΔ oligomers when present 
inside the cells. 15 hours after delivery of protein inside SH-SY5Y cells, TauRDΔ 
oligomers were able to induce Tau aggregation inside the cells. The aggregation was 
analyzed by counting ThS positive cells using flow cytometry. 
The number of ThS positive cells after treatment (delivered inside the cells) with 
TauRDΔ monomer (10µM) (0.515%; Figure 4.29 d) increased significantly compared to 
control (Figure 4.29 a, b and c).  However, the number of ThS positive cells in TauRDΔ 
oligomer (10µM) transfected cells (5.99%; Figure 4.29 g) was increased to 12-fold 
higher than the level achieved by monomers. TauRDΔ oligomers showed a 
concentration dependent increase in the ThS positive cells (Figure 4.29 e,f and g). 
We also used anti-aggregant mutant (TauRDΔ-PP) monomeric protein which generated 
5-fold less ThS positive cells (0.11%) (Figure 4.29 h) compared to pro-aggregant 
TauRDΔ monomers (0.515%) and 50 fold less ThS positive cells compared to TauRDΔ 
oligomers delivered cells (5.99%) (Figure 4.29). This result demonstrates that TauRDΔ 
oligomers could act as seeds and assemble to ThS positive Tau aggregates. The 
likely explanation for the increase in the ThS positive cells in TauRDΔ monomers 
transfected cells could be the presence of small oligomeric species in the monomer 
sample when delivered to the cells. 




Figure 4.29 Intracellular delivery of Tau
RDΔ
 oligomers causes aggregation of Tau  
SH-SY5Y cells were treated with Tau
RDΔ
 monomers or oligomers (intracellular delivery using Xfect 
transfection reagent kit) for 15 h. 1 h prior to the 15 h of incubation, 0.0005% ThS dye was added for 1 
h and then ThS positive cells were counted using flow cytometry. Increased fractions of ThS positive 
cells were observed in an oligomer concentration dependent manner (up to ~6%) (e, f, g), compared 
with only low numbers of ThS positive cells in monomer transfected cells (~0.5%) (d). (i) Histogram 
summarizing ThS positive fractions in the different conditions. 
4.9.2 TauRDΔ oligomers recruit endogenous Tau into filaments 
 We next investigated the composition of aggregates in the oligomer treated cells. As 
TauRDΔ oligomer treated cells showed more ThS positive cells, it is important to 
demonstrate the composition of aggregates. We delivered TauRDΔ oligomers inside 
SH-SY5Y cells (by Xfect) and incubated them for 15 hours. The lysates of SH-SY5Y 
  Results 
89 
 
cells were separated as soluble and insoluble fractions by centrifugation at 100,000x 
g. Analysis of these lysates by immunoblotting with pan Tau antibody K9JA 
demonstrated a large amount of aggregates in the pellet fraction of TauRDΔ monomer 
and oligomer delivered cells. By contrast, there were no aggregates in the pellet 
fraction of the untreated, PBS treated or TauRDΔ-PP monomer delivered cells. As 
observed in flow cytometry, we also observed a concentration dependent increase in 
the aggregates in the pellet fractions of TauRDΔ oligomers delivered cells. Remarkably 
we observed a large amount of aggregates in the monomer sample (Figure 4.30 A) 
but a reduced number of ThS positive cells (Figure 4.29 d). One possible explanation 
is that TauRDΔ monomers induced aggregates do not attain ß-sheet conformation 
detected by ThS dye within 15 hours of delivery. 
We also analyzed whether the endogenous human full length Tau was recruited to 
the growing fibrils. We probed the blot with CP27 (Tau N-terminal specific) antibody. 
As TauRDΔ oligomers do not contain the N-terminal sequence, TauRDΔ protein is not 
detected by the CP27 antibody. Surprisingly, TauRDΔ oligomer-delivered cells showed 
CP27 positive aggregates in the pellet fractions which were absent in the TauRDΔ 
monomer-delivered cells (Figure 4.30 B). This suggests that only TauRDΔ oligomers 
could act as seeds to recruit the endogenous full-length Tau into the aggregates in 
SH-SY5Y cells. We also observed the increase in ThS positive cells in TauRDΔ 
oligomer-delivered cells in N2a cells expressing TauRDΔ protein (data not shown), 
confirming that the results are not cell dependent.  
We next checked the ability of TauRDΔ oligomers to induce the aggregation of Tau in 
rat primary hippocampal neurons. As expected, we observed a concentration 
dependent increase in the aggregates in the lysates of TauRDΔ oligomer delivered 
cells compared to monomers analyzed by immunoblotting with the K9JA antibody. 
Interestingly we observed less aggregates in the TauRDΔ monomer delivered cells 
unlike in SH-SY5Y cells (Figure 4.30 C).  
We also checked the ability of fibrils to induce aggregation. TauRDΔ fibrils generated 
in vitro and delivered into cells generated less aggregates compared to the TauRDΔ 
oligomer treated cells, as analyzed by blots of cell extracts. However, it is not known, 
whether the aggregates observed in the gel pockets are the transfected fibrils or  






  oligomers recruit endogenous Tau into filaments 
Tau
RDΔ
 protein was transfected into SH-SY5Y cells and rat primary hippocampal neurons. A) 
Sedimentation of lysates of SH-SY5Y cells showed that there is an oligomer concentration dependent 
aggregation of Tau confirmed by western blotting using K9JA antibody. S – Supernatant; P – Pellet. B) 
The same blot was re-probed with CP27 antibody (N-terminal specific antibody). It showed that the 
endogenous full length Tau was aggregated along with the transfected oligomers. C) Primary rat 
hippocampal cell (DIV 21) lysates also revealed that the aggregation of Tau is concentration 
dependent. Tau
RDΔ-PP 
monomers did not aggregate in SH-SY5Y and rat primary hippocampal neurons. 
(D) Tau
RDΔ
 oligomer transfected primary hippocampal neuronal lysates displayed 12E8 positive 
phosphorylated Tau in the gel pockets, confirming that the aggregates are phosphorylated which was 
absent in the anti-aggregant transfected cell lysates. 
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newly formed aggregates. As expected, TauRDΔ-PP monomers delivered into cells did 
not cause aggregation at all, as there was no protein detected in the gel pockets 
(Figure 4.30C).  
We next investigated whether the aggregates formed are phosphorylated.  We 
observed a concentration dependent increase in the 12E8 positive aggregates in the 
gel pockets of lysates delivered with TauRDΔ oligomers (Figure 4.30 D). There was 
less 12E8 positive aggregates in the TauRDΔ monomer delivered cells and no 12E8 
positive aggregates in the TauRDΔ-PP delivered cells (Figure 4.30 D) suggesting that 
TauRDΔ oligomers induce the aggregation in rat primary hippocampal neurons, and 
the aggregates are phosphorylated at KXGS motifs 
4.9.3 TauRDΔ oligomers cause early apoptosis to the SH-SY5Y cells 
The preceding experiments showed that TauRDΔ oligomers delivered into cells can 
cause the aggregation of endogenous Tau. An open question was whether this 
aggregation could compromise the health of the cell. In order to understand the toxic 
properties induced by the TauRDΔ oligomers, we determined the fraction of annexin V 
positive cells (an early apoptotic marker) in the TauRDΔ oligomer, monomer and buffer 
treated cells. TauRDΔ oligomers delivered into cells caused early signs of apoptosis in 
a TauRDΔ-oligomer-dependent manner within 15 hours. The fraction (~28%) was ~7-
fold higher in TauRDΔ oligomer-delivered cells, compared with transfection of TauRDΔ 
monomers (~4%) (Figure 4.31), or with monomers of the anti-aggregant TauRDΔ-PP. 
This data suggest that TauRDΔ oligomers induce early apoptosis when present inside 
the neurons. 
 






 oligomers promote apoptosis in cells 
Tau
RDΔ
 protein was delivered directly into SH-SY5Y cells using Xfect transfection reagent kit and the 
samples were analyzed using annexin V (an early apoptotic marker) by flow cytometry. Note that there 
is a shift in the annexin V positive cells in an oligomer concentration dependent manner. The toxicity 
caused by Tau
RDΔ
 monomers was not significant compared with Tau
RDΔ
 oligomers.  




Tau protein is a natively unfolded protein because of its hydrophilic aminoacid 
composition (Lee et al., 1988). A major role of Tau is the stabilizion of microtubules, 
thereby maintaining the architecture of neurons and enabling axonal transport. There 
are several brain diseases where Tau is pathologically altered, leading to 
hyperphosphorylation, detachment from microtubules, missorting into the 
somatodendritic compartment, aggregation into fibers, synaptic decay, neuronal loss 
and further changes. These diseases are collectively termed "tauopathies" and 
include Alzheimer disease, Frontotemporal dementia, Pick disease, and others 
(Mandelkow and Mandelkow, 2012). It was initially suspected that the fibrillar form of 
Tau ("paired helical filaments") is the toxic species. However, in recent years the 
emphasis shifted to pre-fibrillar forms as the toxic agents. Evidence from mouse 
models (Santacruz et al., 2005, Andorfer et al., 2005, Yoshiyama et al., 2007, Berger 
et al., 2007, Eckermann et al., 2007, Van der Jeugd et al., 2012) and human studies 
(Gomez-Isla et al., 1997, Maeda et al., 2006) suggested that the toxic species could 
be some intermediate oligomeric forms of Tau assembly. However, the nature of the 
oligomeric species remained a matter of debate. 
Earlier, our group demonstrated that the aggregation of Tau protein into fibers is 
based on beta-structure forming hexapeptide motifs (von Bergen et al., 2000). This 
knowledge was exploited in cell and animal models which enhances the beta 
propensity or delete it (pro-aggregant or anti-aggregant tau) which proved that tau 
pathology is closely linked to aggregation (Khlistunova et al., 2006, Eckermann et al., 
2007, Mocanu et al., 2008). The TauRDΔ transgenic mice show strong aggregation of 
Tau, memory impairment and pronounced loss of long term potentiation. However, 
when the TauRDΔ  protein expression was switched on for 14 months and then off for 
1 to 4 months, memory and LTP was recovered, synapse loss was largely rescued,  
but the aggregates decreased only moderately. Surprisingly, the composition of the 
aggregates changed from a mixture of mouse Tau plus human TauRDΔ to  mouse Tau 
only. These mouse models suggested that soluble oligomeric mutant forms of Tau 
might be the toxic species rather than larger fibrillar aggregates. Moreover, the early 
forms of Tau aggregation are likely heterogeneous and do not necessarily have beta 
structure (detectable by ThS), hence there was a need for other markers. Therefore, 
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this work was focussed on preparing homogeneous low-n oligomers and then 
probing their properties and toxic effects with different methods.  
5.1 Stabilization and purification of TauRDΔ protein in vitro 
Several other groups have reported on the generation of Tau oligomers. In most of 
the cases, Tau oligomers are prepared with the aid of inducers like heparin (Sahara 
et al., 2007), arachidonic acid (Patterson et al., 2011), metal ions (Bader et al., 2011) 
and by cross-seeding using other amyloidogenic proteins (Aß and α-Syn) (Lasagna-
Reeves et al., 2010). The oligomers prepared by these methods, probably do not 
exist in AD brains. The advantage of our preparation method is that TauRDΔ protein 
readily forms oligomers without the aid of any inducers due to its enhanced ß-sheet 
propensity. Therefore, these oligomers would be expected to be a better 
approximation to the physiological situation.  
The aggregation kinetics of TauRDΔ protein under different buffer conditions (PBS pH 
7.4 and TBS pH 9.0) was performed in vitro in order to determine optimal conditions 
for oligomer preparation. It was shown earlier in our lab that TauRDΔ protein under 
PBS pH 7.4 conditions aggregates rapidly (Kumar et al., 2014). Similarly, the 
condition TBS, pH 9.0 is also favorable for formation of PHFs of full length Tau 
protein (Goux, 2002). Consistent with these earlier data (Kumar et al., 2014), we 
observed that under both buffer conditions (PBS and TBS) aggregation occurs in a 
similar fashion. i.e., the aggregation reaches a maximum at 8 hours and stays 
stationary till 72 hours. There was no significant difference in the ThS positive 
aggregates in both buffer conditions (Figure 4.4 A). However, EM and AFM revealed 
short fibrils and many oligomers in the TBS, pH 9.0 condition whereas long twisted 
fibrils were formed in the PBS pH 7.4 condition (4.6 B and E), suggesting that TBS, 
pH 9.0 condition favors the oligomer formation and thus we prepared our oligomers in 
TBS, pH 9.0 buffer. 
As the oligomers prepared in TBS pH 9.0 were not SDS stable, they could not be 
separated by size exclution chromatography (SEC) (Figure 4.7 B, C). Thus we 
searched for alternative methods to stabilize the TauRDΔ oligomers. It was reported 
that ECGC inhibits the aggregation of α-synuclein and induces the formation of off-
pathway oligomers which are not toxic (Ehrnhoefer et al., 2008). EGCG has also 
been shown to inhibit the aggregation of His-TauRDΔ (Wobst et al., 2015) and more 
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specifically SDS stable insoluble oligomers. We used EGCG to inhibit the 
aggregation of TauRDΔ protein (without His tag). Unlike the His-TauRDΔ, TauRDΔ readily 
forms filamentous aggregates within 72 hours. The presence of EGCG reduces the 
length of the fibrils and increases the oligomers (Figure 4.9) . Thus it appears that the 
assembly competence of TauRDΔ was reduced by the N-terminal His tag. We 
observed that the EGCG increases the formation of SDS stable low-n oligomers and 
reduces the aggregates and SDS stable insoluble oligomers (Figure 4.8, Figure 
4.10). However, the SDS stable soluble oligomers induced by EGCG were not 
separable by SEC due to the small difference in the molecular weight of monomers, 
dimers and trimers. We therefore turned to a cross-linking approach to stabilize the 
TauRDΔ oligomers. 
We used glutaraldehyde to cross-link the TauRDΔ oligomers. As low as 0.01% GA 
was sufficient to cross-link the TauRDΔ oligomers and achieved stable dimers, trimers 
and tetramers in SDS denaturing gels. We observed that indeed the TBS pH 9.0 
condition favors the oligomer formation better than PBS pH 7.4, as we observed 
more oligomers in the chromatogram (Figure 4.12). The purified oligomers were 
stable at 4°C for more than a month, as analyzed by SEC and AFM (data not shown). 
The stabilized TauRDΔ oligomers (TBS pH 9.0, GA fixed) were SDS stable and were 
separable by size exclusion chromatography. However, only half of the fractions 
contained only oligomers, the remaining half contained a mixture of monomers and 
oligomers (Figure 4.13). The purified oligomers display a 4-fold increase in ANS 
fluoresence intensity confirming that the oligomers are structurally modified. ANS is a 
sensitive marker of protein conformation and is often used to study protein folding 
(Semisotnov et al., 1991).  It binds to exposed hydrophobic residues as well as 
cationic side chains (Arg, Lys) (Gasymov and Glasgow, 2007) which are numerous in 
TauRDΔ (20 out of 129 aa or ~15%). Thus the increase in ANS fluorescence during 
oligomerization could be explained by a conformational change exposing more Arg 
and Lys residues (Figure 4.14 B). Although conformational changes are evident in 
the oligomers, they do not attain ß-sheet structure, as judged by the low ThS 
fluorescence (Figure 4.14 A) and CD measurements (Figure 4.14 C). Most of the 
oligomers are less than 6nm in AFM height images suggesting that they are low-n 
TauRDΔ oligomers.   
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Since we observed an increase in the intensity of ANS in TauRDΔ oligomers, hinting at 
an increased exposure of hydrophobic residues, we tested hydrophobic interaction 
chromatography to purify the oligomers. This proved to be successful, in particular 
the Butyl FF 16/10 column separated the TauRDΔ oligomers from TauRDΔ  monomers 
with high purity (>90%). These purified oligomers were SDS stable, with increased 
ANS intensity, yet a random coiled secondary structure (as judged by CD), and 
lacking pronounced beta structure, as seen by the low ThS intensity. 
5.2 Structural properties of purified low-n TauRDΔ oligomers 
The structural morphology of TauRDΔ oligomers was analyzed by atomic force 
microscopy and dynamic light scattering. The purified TauRDΔ oligomers demonstrate 
heights in the range of 3.7 ± 2.0 nm measured from AFM height images (Figure 4.18 
A and B) and display globular shape which is clearly visible in the amplitude image 
(Figure 4.18 C). We also observed some higher-order oligomers in AFM height range 
of more than 6nm which could correspond to maximum of 10-mers. Such higher 
order oligomers might act as seeds for the rapid aggregation of TauRDΔ. 
When measuring the size of oligomers by dynamic light scattering we found a 
hydrodynamic radius Rh ~6 nm, compared to ~3 nm for monomers (Figure 4.19). 
Similar to our results, others also found that the 4R repeat domain Tau in solution 
stays as dimers and displayed a hydrodynamic radius of 3.1 nm (Yao et al., 2003). 
Several rapidly aggregating mutant TauRD species (for example: P301L 4R Tau) 
also displayed hydrodynamic radii of ~3.1 nm. Hence the authors concluded that all 
4R Tau proteins with or without mutation exists as dimers in solution (Yao et al., 
2003). Earlier our group also showed that the Stokes radii of 3.0 nm for the dimers 
formed from K12 construct (3R repeat domain Tau) based on gel filtration 
chromatography analysis (Wille et al., 1992). Earlier findings (Wille et al., 1992, Yao 
et al., 2003) along with the present data argue that TauRDΔ oligomers exhibit 6nm 
radius which corresponds to a tetramer of TauRDΔ protein, roughly consistent with 
SDS gel analysis where we observed dimers, trimers and tetramers. Thus the 
structurally characterized oligomers could be used to understand the functional 









Figure 5.1 Characterization of Tau
RDΔ
 oligomers 




 oligomers expose 
hydrophobic and positively charged residues on their surface (ANS) which aids in the separation of 
oligomers from the monomers by hydrophobic interaction chromatography methods (HIC). The purified 
oligomers have altered conformation (ANS) with less or no ß-sheet structure (ThS and CD). The 
oligomers are roughly globular in shape and in the height ranges from 3.7 ± 2.0 nm (AFM). The 
hydrodynamic radii for oligomers are ~6 nm (DLS) which corresponds to tetramer consistent with SDS 
gel analysis. 
 
5.3 Functional properties of pro-aggregation TauRD oligomers 
5.3.1 Extracellular effects of TauRDΔ oligomers 
The major question in the field of Alzheimer disease (and Tauopathies in general) is 
the toxic species of Tau and the mechanisms of toxicity. Several groups have studied 
the toxic properties of Tau aggregates, especially PHFs, but more recent evidence 
suggests that soluble or prefibrillar forms of aggregates are responsible for toxicity 
and cell death rather than the higher aggregates or PHFs(Haass and Selkoe, 2007). 
In fact there is a debate whether PHFs are toxic or protective to neurons 
(Trojanowski and Lee, 2005). In the last decade, Tau oligomers received much 
attention because the toxic effects of Tau protein preceded NFT formation in mouse 
models (Andorfer et al., 2005, Spires et al., 2006, Yoshiyama et al., 2007, Polydoro 
et al., 2009, Van der Jeugd et al., 2012, Eckermann et al., 2007). Tau is primarily an 
intracellular protein, and it is believed that Tau alone is enough to cause toxicity, at 
least in familial Tauopathies based on Tau mutations. Consistent with this, Tau inside 
cells can cause microtubule destruction, disruption of transport, deregulation of 
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signaling or degradation pathways (Blair et al., 2013, Gotz et al., 2010, Wang et al., 
2007, Zempel et al., 2010, Zempel et al., 2013).  
On the other hand, Tau can occur outside neurons and has been proposed to cause 
the spreading of Tau pathology in the brain (Braak and Braak, 1991b). Tau protein 
(total Tau and phospho Tau) is enhanced in the CSF (cerebro-spinal fluid) of human 
AD brains (Hampel et al., 2010). The concentration of Tau in the interstitial fluid is 
45ng/ml (equivalent to ~1nM) (Yamada et al., 2011) which is 1000 times less than 
the intracellular concentration of Tau (estimated at ~1µM, (Drubin et al., 1985)). 
Extracellular tau is also being released from cell lines and neurons via multiple 
pathways (Chai et al., 2012, Hall and Saman, 2012, Saman et al., 2012, Simon et al., 
2012), strongly supporting the notion that secretion of tau protein may be an 
important biological function or dysfunction of tau, especially in disease. These 
findings suggest that extracellular tau could be a physiological process and may also 
have toxic properties.  
In support of this, earlier it was shown that, extracellular monomeric Tau is enough to 
cause the toxicity in neuronal cells by elevating the intracellular calcium level through 
M1/M3 muscarinic receptor stimulation which leads to endocytosis of extracellular tau 
thereby causing cell death (Gomez-Ramos et al., 2006, Gomez-Ramos et al., 2008). 
Moreover extracellular human Tau can spread between CNS neurons through non-
synaptic or synaptic mechanisms (Le et al., 2012). Extracellular monomeric Tau 
protein can be endocytosed and is able to propagate the aggregation of endogenous 
Tau (Michel et al., 2014). This is possible not only for monomeric Tau protein, but 
also for the fibrillar form of Tau which can be endocytosed, induces aggregation and 
propagates trans-cellularly. (Kfoury et al., 2012). The soluble aggregates of Tau 
could enter via dynamin driven endocytosis (Wu et al., 2013) and proteoglycan 
mediated macropynocytosis (Holmes et al., 2013). 
Tau protein can interact with cell membranes and could modify their properties 
(Jones et al., 2012). In support of this, Tau oligomers were shown to damage the cell 
membrane in SH-SY5Y cells (Lasagna-Reeves et al., 2010, Flach et al., 2012) 
whereas the monomers did not cause the membrane damage.  These evidences 
suggest that even the extracellular Tau might cause toxicity by different mechanisms. 
  Discussion 
99 
 
We therefore analyzed the toxic properties of purified TauRDΔ oligomers in neuronal 
cell culture and organotypic slice culture models. Earlier it was demonstrated that the 
toxicity induced by Aβ-oligomers was dependent on the assay used (Wogulis et al., 
2005) We therefore checked the toxicity of TauRDΔ oligomers by different assays, 
including MTT, XTT, alamar blue and LDH release assay. We did not observe any 
reduction in the cell viability in SH-SY5Y cells and in primary cortical neuronal cells 
as judged by the above assays (Figure 4.20). There was no membrane disruption by 
the LDH assay (Figure 4.20) consistent with the data of Kumar et al (Kumar et al., 
2014). 
We also checked the ability of TauRDΔ oligomers to cause toxicity in hippocampal 
slice culture models, as these mimic the hippocampus of the human brain and retain 
the connections between neurons and glia cells. The results were unexpected as 
there was no loss of neurons (analyzed by the density of NeuN positive cells) and no 
membrane damage (by the LDH release assay) (Figure 4.22). Since the oligomers 
are cross-linked and might block some  active site, we also checked the toxic effects 
of oligomers before purification, but with the same results (no loss of cell viability and 
membrane integrity) (Figure 4.21). We conclude that the TauRDΔ oligomers are not 
toxic to neuronal cells and hippocampal slices by standard "classical" assays. 
These results are in contrast to other publications (Lasagna-Reeves et al., 2010, 
Flach et al., 2012, Tian et al., 2013). Since the TauRD repeat domain protein does not 
contain the N-terminal or C-terminal domains of Tau, we investigated the relationship 
between Tau domains and toxicity, using Tau variants with different domain 
compositions. This, too, did not explain the discrepancies in experimental results 
(Figure 4.23). We therefore assume that they are due to different methods of 
oligomer preparation. 
The TauRDΔ mouse model showed pronounced tau pathology at 10 months of age, 
including loss of spines, which was reversed when the Tau expression was switched 
off for periods of 1 to 4 months (Sydow et al., 2011). Therefore we next investigated 
the more subtle effects such as spine loss caused by these oligomers. As expected 
we observed pronounced loss of spines up to 50% when TauRDΔ oligomers (1µM) 
were applied extracellularly to rat primary hippocampal neurons.  
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Oxidative stress plays an important role in AD pathogenesis. (Butterfield et al., 2001)               
and oxidative stressors play a critical role in neurofibrillary pathology leading to Tau 
hyperphosphorylation (Borza, 2014). In Tauopathy mouse models, oxidative stress 
eventually leads to cell death (Cente et al., 2006).Therefore, we investigated whether 
TauRDΔ oligomers cause an increase in intracellular reactive oxygen species in rat 
primary hippocampal neurons. This was observed within minutes of incubation with 
oligomers and that was increased with oligomer concentration (Figure 4.25).  The 
mechanism responsible for ROS production by TauRDΔ oligomers is not yet 
understood. A possible pathway may be through the membrane enzyme NADPH 
oxidase (Gao et al., 2012), as the increase in ROS occurred within a minute. The 
NADPH oxidase complex generates extracellular superoxide which is converted into 
hydrogen peroxide outside the cells. This is then able to cross biological membranes 
and oxidize membrane lipids (Hernandes and Britto, 2012). This would explain the 
rapid increase in ROS upon addition of  TauRDΔ oligomers.  On the other hand, the 
mitochondrial membrane potential is not disturbed in oligomer treated cells (as 
judged by JC1 staining) (data not shown) so that it is unlikely that mitochondrial ROS 
production is involved within the short time. 
There is a strong correlation between the increase in ROS production and calcium 
elevation. Mitochondria are both generators and targets of ROS. Thus the 
dysfunction of mitochondrial energy metabolism leads to impairment in calcium 
homeostasis (Fu et al., 2014). Superoxide ions formed in the extracellular space can 
enter into cells through the chloride channel-3 and cause the elevation of the 
intracellular calcium level (Hawkins et al., 2007). Hence we investigated the 
intracellular calcium level by fura-2 imaging and observed a gradual increase up to 
20 minutes, clearly later than the increase in ROS (Figure 4.26). The source of the 
calcium is not yet known. However, we assume that the calcium should have entered 
from the extracellular space through the leaky cell membrane as the ROS might 
oxidize the membrane lipids. 
Oxidative stress and calcium elevation have been implicated in Aβ-oligomer 
mediated neurotoxicity (Fu et al., 2014). Aß-oligomers are also shown to cause 
synapse loss via calcium dysregulation, Tau phosphorylation and missorting (Zempel 
et al., 2010). Since we observe calcium dysregulation and synapse loss in neurons 
treated with TauRDΔ oligomers, we asked whether Tau missorting also follows the 
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calcium elevation to cause the spine loss. TauRDΔ oligomers did not cause missorting 
of Tau in rat primary hippocampal neurons (Figure 4.27). The pathological changes 
caused by TauRDΔ oligomers are summarized in Figure 5.2  










 oligomers induce the ROS production (green color) in rat primary hippocampal neurons within 
2 minutes of incubation followed by an increase in the intracellular calcium level (red color) (saturation 
at 20 min) and later loss of spines at 3 hours (yellow color). 
 
5.3.2 TauRDΔ oligomers as intracellular seeds 
Since Tau is an intracellular protein and forms neurofibrillary tangles within neurons, 
it is important to understand the role of purified TauRDΔ oligomers in neurons. Studies 
from model organisms proved that the filaments are formed from monomers (Gotz et 
al., 2007), and that endogenous and transfected Tau can co-polymerize (Mocanu et 
al., 2008, Van der Jeugd et al., 2012). In vitro and in vivo studies showed that seeds 
are necessary for the filament formation. (Friedhoff et al., 1998b, Schweers et al., 
1995, von Bergen et al., 2000, Lasagna-Reeves et al., 2012a). Seeding could take 
place either by nucleation within cells (as is the case, say, for actin or microtubule 
assembly), or by transfer of seeds from outside the cells, as discussed below.  
Experiments in cultured cells have shown that extracellular Tau aggregates can be 
endocytosed by cells and can act as seeds to induce the misfolding and aggregation 
of intracellular Tau (Frost et al., 2009a, Nonaka et al., 2010, Frost et al., 2009b, Guo 
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and Lee, 2011, Michel et al., 2014). These seeds can spread between CNS neurons 
via a variety of non-synaptic mechanisms (naked Tau release, exosomes and 
membrane vesicles) or synaptic mechanisms (Le et al., 2012).  Mouse models also 
showed that injection of brain homogenates from mice expressing mutant Tau into 
brains of normal mice leads to the conversion of naive Tau protein into NFT like 
aggregates in the recipient mice (Clavaguera et al., 2009). 
The spreading of Tau pathology was initially observed in human brains where the first 
NFTs occur in the entorhinal cortex, and the pathology progresses in a 
topographically predictable manner across limbic and association cortices along 
anatomical connections (Braak stages) (Braak and Braak, 1991a, Braak and Braak, 
1991b). This spreading of pathological features could be caused by several 
mechanisms, e.g. electric or chemical signalling (e.g. cytokines), or by transfer of Tau 
itself in a pathological state (Brundin et al., 2008). The latter view gained momentum 
with the discovery that any form of Tau protein (monomer (Michel et al., 2014), 
oligomer (Lasagna-Reeves et al., 2012b) and fibril (Iba et al., 2013)) can be 
transferred from neurons to neurons and cause the local accumulation of 
endogenous Tau (Medina and Avila, 2014, Clavaguera et al., 2015). 
It was shown previously that even in vitro prepared PHF can act as seeds (Guo and 
Lee, 2011). However, recent data of Lasagna-Reeves and coworkers argued against 
this observation, as PHFs from AD brain injected into wild type mice did not cause 
propagation of Tau pathology, supporting the notion that AD PHFs do not act as 
seeds (Lasagna-Reeves et al., 2012a). This could be explained by the procedure - in 
vitro prepared PHFs were ultrasonicated to break down long fibrils into short ones 
and oligomers and then delivered into cells (Guo and Lee, 2011). As electron 
microscopy is not suitable for characterizing small oligomers, the effects of oligomers 
might have been overlooked.  
In most of the above-mentioned studies, the seeds were applied extracellularly and 
the effects checked intracellularly. We therefore investigated the role of Tau protein 
as in seeding in SH-SY5Y neuroblastoma cells. We applied the TauRDΔ monomers 
and oligomers extracellularly and then counted ThS positive cells by flow cytometry 
to analyze the ability of oligomers to be endocytosed and act as seeds. When TauRDΔ 
oligomers were present in the medium for 15 hours we observed a 2 fold increase in 
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the ThS positive cells compared to monomer treated cells (Figure 4.28). Although the 
increase in ThS positive cells after oligomer treatment was significant, the overall 
number of ThS positive cells was very low.   
We therefore employed a protein transfection method which is a powerful tool for 
elucidating a protein function in a cell, and plays an important role in the fields of cell 
biology and drug discovery (Oba and Tanaka, 2012). Protein transfection approach 
have been used earlier as well to study the seeding efficiency of Tau aggregates 
(Guo and Lee, 2011).  Using this approach (Xfect protein transfection reagent) we 
observed that TauRDΔ oligomers caused the accumulation of endogenous Tau in 
SH-SY5Y cells to the ThS positive aggregates, and that oligomers were by far the 
most efficient Tau species (Figure 4.29 and Figure 4.30). This is consistent with 
reports that oligomers (but not PHFs) isolated from AD brain caused the spreading of 
Tau pathology in mice (Lasagna-Reeves et al., 2012a). We observed an increase in 
the ThS positive cells in TauRDΔ monomer delivered cells compared to PBS treated 
cells. This might be interpreted to mean that the monomeric TauRDΔ could self-
aggregate (ThS positive), as the analysis shows that the aggregates in SH-SY5Y 
cells do not contain the endogenous Tau (Figure 4.30). However, since TauRDΔ 
monomer preparations contain a low amount of low-n oligomers (Figure 4.12 A and 
C) (Kumar et al., 2014) one cannot rule out that they initiate nucleation and hence a 
ThS response. 
The effect of intracellular TauRDΔ oligomers (ThS positive cells) was 50 fold higher 
compared to the effect of oligomers when applied extracellularly to SH-SY5Y cells. 
(Figure 4.28 and Figure 4.29).  




Figure 5.3 Effects of intracellular delivery of Tau
RDΔ
 protein 
Protein transfection (Xfect reagent) of Tau
RDΔ 
monomer to SH-SY5Y cells induce the self-aggregation 
of Tau and does not recruit the endogenous Tau from SH-SY5Y cells whereas Tau
RDΔ 
oligomers 
recruit the endogenous tau into the growing aggregates and induce the apoptosis (annexin V positive 
cells). 
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The mechanism of TauRDΔ oligomer entry into the cells is not well understood. We 
assume that the TauRDΔ oligomers can be endocytosed, but the amount of 
endocytosed Tau is too small to cause the aggregation, or the incubation time is too 
short. The protein derived from the monomer or oligomer-delivered cells shows 
almost equal amounts of aggregates in the gel pockets (Figure 4.30) but ThS positive 
cells were 12 times lower in the case of monomer-treated cells. This suggests the 
presence of amorphous aggregates, rather than fibers in the monomer delivered cells 
(Figure 4.29).  
Similar to results from the SH-SY5Y cells, we noticed in rat primary hippocampal 
neurons TauRDΔ oligomers cause aggregation of Tau, and that the aggregates are 
phosphorylated at KXGS motifs (Figure 4.30). This is consistent with earlier results of 
others that the seeds induce the aggregation of endogenous Tau at elevated 
phosphorylation (Guo and Lee, 2011, Clavaguera et al., 2009). When oligomers of 
TauRDΔ are present inside cells, they causes early apoptosis (seen by annexin V 
staining) (Figure 4.31). This effect does not occur when TauRDΔ oligomers are added 
outside cells. 
To conclude, TauRDΔ oligomers show some toxicity to synapses when present 
extracellularly. However, toxicity is much more pronounced when oligomers are 
introduced into cells, leading to strong aggregation and pathology.
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Protein purification chemicals: 
10 X CB Buffer 
Chemical Weight Stock Volume 
0.2 M Na-Mes 42.646 g - - 
10mM Na-EGTA 3.804 g 0.5M 20ml 
10mM MgCl2  2 g  1 ml 
Make up to 1 liter with double distilled water, pH 6.8. Store at 4°C. Prepare the whole 
solution once or prepare it from stock. 
 
Re Suspension Buffer Composition: For 100 ml 
Chemical Stock Volume 
CB Buffer 10 X 10 ml 
DTT 1 M 0.5 ml 
PMSF 0.1 M 2 ml 
Leupeptin 10 mg/ml 100 µl 
Pepstatin A 5 mg/ml 200 µl 
benzamidine 1M 200 µl 
MQ H2O  87 ml 
 
Mono S A Buffer 10 X  
Chemical 10X Stock Volume for 1X 
20 mM Na-MES 0.2 M 100ml 
50 mM  NaCl 5 M 10ml 
2 mM DTT 1 M 2 ml 
1 mM  Na-EGTA 0.5 M 2 ml 
1 mM  MgSO4 1 M 1 ml 
0.1 mM PMSF 0.1 M 1 ml 







Mono S B Buffer (250 ml suffices for a single run) 
Chemical Stock Volume 
20 mM Na-MES 0.2 M 100ml 
1M  NaCl 5 M 200ml 
2 mM DTT 1 M 2 ml 
1 mM  Na-EGTA 0.5 M 2 ml 
1 mM  MgSO4 1 M 1 ml 
0.1 mM PMSF 0.1 M 1 ml 
Make up to 1Liter; pH 6.8; Sterilize; PMSF and DTT should be added fresh. 
 










40% Acrylamide 10.6 ml 15 ml 25.6 ml 5.4 ml 
1M Tris HCl pH 8.8 22 ml 22 ml 22 ml - 
0.25 M Tris HCl pH 6.8 - - - 27 ml 
H2O 26.4 ml 22 ml 11.5 ml - 
H2O + Bromophenol 
Blue - - - 20.9 ml 
10 % SDS 600 µl 600 µl 600 µl 540 µl 
TEMED 120 µl 120 µl 120 µl 108 µl 
10% APS 65 µl 65 µl 65 µl 150 µl 
 
5X SDS sample buffer 
0.32M Tris-HCl, pH 6.8; 10% SDS; 50% Glycerol; 1.43M ß-ME; and  
10-2% Bromophenolblue 
 
1X SDS running buffer 








10X blotting buffer or Transfer buffer 
390 mM Glycine; 480 mM Tris; 0.3% SDS; Make up to 1 liter with doubly distilled 
water.  
 
1X blotting buffer or Transfer buffer 
100 ml of 10X blotting buffer; 50 ml 100% methanol; Make up to 1 liter with doubly 
distilled water.  
 
10X TBST 
100 mM Tris; 1.5 M NaCl; 0.5% Tween 20; Make up to 2.5 liters with doubly distilled 
water. Adjust the pH to 7.5 
 
Stripping buffer 
0.2M glycine; 1mM EDTA-Na; 0.5M NaCl, pH 2.5. 
 
Coomassie Stain: 
25% isopropanol; 10% acetic acid; 0.05% coomassie R-250; Make up to 200 ml with 
doubly distilled water. 
 
Coomassie destaining solution: 
Intensive: 
2.5 L ethanol; 2.0 L doubly distilled water; and 0.5 L acetic acid 
Normal: 
250 ml ethanol; 375 ml acetic acid; and 4375 ml doubly distilled water 
 
Silver staining: 
Fixative: 30% ethanol and 10% acetic acid 
Cross-linking reagent: 30% ethanol; 0.5M sodium acetate; 0.2% sodium thio 
cyanate and 0.5% glutaraldehyde 
Silver nitrate staining solution: 
0.1% silver nitrate; and 0.02% formaldehyde 
Developing solution: 
2.5% sodium carbonate; 0.01% formaldehyde. 




50mM EDTA, pH 8.0 
 
AFM 
Adsorption buffer (PBS) 
137 mM NaCl; 8 mM NH2PO4, 2.7 mM KCl; and 1.5 mM KH2PO4 adjusted to pH 7.4. 
Imaging buffer  
10 mM Tris–HCl; 50 mM KCl; adjusted to pH 7.4. 
 
Cell culture chemicals: 
SH-SY5Y cells culture medium: 
15% FBS; 1% penicillin and streptomycin; diluted in DMEM medium followed by filter 
sterilization. 
SH-SY5Y cells freezing medium: 
50% FCS; 30% DMEM; 20% DMSO;  
Preparation and sterilization using syringe filters. The filtered solution diluted 1:1 to 
the culture medium. 
 
Primary rat neuronal cell growing:  
Plating medium: 
10% Horse serum; 1% penicillin and streptomycin; 1mM pyruvate; diluted in DMEM 
medium followed by filter sterilization. 
Neurobasal medium: (Neuron specific medium) 
1% penicillin and streptomycin; 2% B27 serum supplement; 2mM L-glutamine 
make up the volume to 500 ml with neurobasal medium. All the additives should be 
filter sterilized before the addition.  
Neurobasal medium with AraC: (To inhibit the growth of the astrocytes) 
AraC diluted with Neurobasal medium at a 1:6000 ratio for rat neuronal cells; 1:3000 










MEM media – 50% (200ml) , HBSS – 25% (100 ml), horse serum – 25% (100ml) , 
penicilin and streptomycin – 1% (4ml) , glucose – 0.9%, (1.8g) . The culture media 
was prepared, filter sterilized and stored at 4°C until further use. 
 
2X Lysis buffer 
100 mM Tris-HCl, pH 7.4; 20% glycerol ; 2% NP 40 detergent; 10mM DTT; 2mM 
EGTA; 40mM NaF and 2mM Na3VO4. 
Working lysis buffer 
2X lysis buffer; 150mM NaCl; 1X complete protease mini, 5mM CHAPS, 100U 
benzonase and 5µM okadaic acid. Make up these chemicals with distilled water to 
the desired volume. 
 
Sarcosyl extraction: Buffer H 
10mM Tris-HCl, pH 7.4; 0.8M NaCl; 1mM EGTA; 10% Sucrose; 1mM PMSF and 1X 
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